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INTRODUCTION 
 Man is a wonderful creature blessed by God.  Imagination and laughter are 
milestones on the way that distinguishes mn from other animals.  Of mere living, no man 
was ever proud; but the god life has always been his aim. 
 The aim of the History of Siddha Medicine is to present a faithful, clear and vivid 
picture of this system in all its manifestation and ramifications with all its inherent 
problems and relevancy to present age from its very beginning down the ages, as an 
integral component of the patterns of culture through which this system has passed in 
different ages and in different areas. 
 The unique nature of this system is its continuoes service to humanity for more 
than five thousand years in combating diseases and in maintaining its physical, mental, 
and moral health, while many of its contempraries had completed their courses long long 
age, since its origin, development and remifications have become obscure, any literary 
research on this subjective, to be scientific and useful, should commence with a 
comparative study of the medicines of those ancient civilizations, which will illuninate 
many of the dark cornersmof our systems. 
 The enormous pharmacopoeia containg vegetable, animal, and mineral products 
at times, including substance of disgusting character; empirical treatments, under the 
guise of magic exoricsm, incantation, pilgrimage, percegrination, mountainering and 
similar activities. 
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 Many principles on which very efficacious siddha medicines are prepared and 
treatments given, make us believe they had a detailed understanding of many of the 
fundamentals of biology, such as how enzymes work, how proteins perform mechanical, 
protective and catalytic function, and how proteins perform mechanical, protective and 
catlytic functions, and how glucose is metabolised for energy.  The knowledge of the 
function of the enzymes Siddhas put into practice, is really marvellous when we consider 
the different ordinarilly inexplicable effective simple treatments of this system. 
 These medicines may be roughly divided into three classes as (1) Miracle 
medicines, (2) sophisticated medicines, and (3) Common medicines.  Miracle medicines 
are becoming rare and should be learned direct from the masters who, having undergone 
all forms of initiation and hazards of apprenticeship, have reached perfection in all 
respects.  Sophisticated medicines may be scientifically prepared and used by the well 
trained physicians without much risk.  Common medicines are the most simple and very 
cheap things which were in wide use till the beginning of this century and are still in use 
in remote rural parts of our country. 
 Man is hale  and healthy when his life moves along with nature when he violates 
against it he is oushed into mental stress, detriorates his physique and ultimately his 
sound mind. 
 Todays mdern industrialization imbalances the Ecosystem which paves way for 
many disease.  To uproot these diseases there should be a system of medicine which goes 
hand in hand with the nature. 
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 In the legend of science the only system with rich Dravidian culture is the noble 
Siddha System of Medicine.  It is holistic and treats the complete individual and not 
merely the disease.  The treatment vries for different individuals based on their 
constitution (Prakriti) and dietary habits. 
 It is pround and pleasure for the author to be in this field and to take up the 
dissertaion on the disease that leads to many patients in despair. 
 The author has chosen “Azhal keel Vaayu” (Osteoarthritis), one of the 
degenerative disease as the topic for dissertation subject. 
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AIM AND OBJECTIVES 
Azhal keel Vaayu (Osteoarthritis) is a very common condition affecting the joints 
more frequently with aging. It’s a major cause of morbidity of the working force, 
throughout the world. 
The extrapolation rate of osteoarthritis in our country is 78, 341,013 and the 
estimated population is 1, 065, 070, 607 (US census bureau, international Date Base – 
2007) 
So the author is much interested in choosing this disease as the topic for 
dissertation and treating the same with the help of  Mirudharsingi Chunnam–65mg–twice 
a –day internally and poochu ennai externally. 
The aim and objective of this dissertation, is stated as below. 
1. Siddha system of medicine should reach the entire society of the world.  
2. The unique aspect of Siddha principles namely the three dosham theories with 
respect of  body constitution (yaakai), taste (suvai) and seasonal variation 
(Paruvakalam) are interpreted with the disease. 
3. Relevant evidence from various Siddha literature and other system of medicine to 
be attached. 
4. To study the incidence of the disease with respect to age, Gender, socio-economic 
status, habit and family history. 
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5. To know the correlation of aetiology, clinical features, signs and symptoms of 
Azhal keel vaayu in siddha aspect with osteoarthritis in modern aspect. 
6. To have a detailed clinical investigations. 
7. To have a clinical trial on Azhal keel Vaayu with Mirudharsingi Chunnam 
internally and poochu ennai externally. 
8. To estimate the efficacy of Mirudharsingi Chunam and Poochu ennai  
9. To evaluate the biochemical, pharmacological and toxicological reports of 
dissertation medicine. 
10. To pave way for further research work in future. 
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SIDDHA ASPECTS 
 Siddhars, spiritual scientists explored and explained the reality of Nature and its 
relationship to man by their yogic awareness.  According to Siddha philosophy, man is 
nothing but a miniature world containing the five basic elements. 
 Universe originally consisted of atoms which contributed to the five basic 
elements (Pancha boothas) namely, Earth, Water, Fire, Air and Ether which corresponds 
to the five sense of the human body and they were the fundamentals of all human body 
and all the corporal things.  
 The Earth (l{<*!gives shape to the body and release its energy, Bones, muscles, 
nerves represent it in the body. 
 The Water (fQI*!makes the earth supply and helps in the transmission of energy, 
serum, lymph, saliva, etc., represent it in the body. 
 The Fire (kQ*!makes the form of the body steady and gives vigour and stimulation.  
Digestion and circulation represent it in the body. 
 The Air (utq*!Ignites the fire and works as a life carrier and is the support of all 
contact and exchange.  Respiratory and nervous system represent it in the body. 
 The Ether (Ngibl<*!is the creater of life itself in the body. 
 A harmonious combination and function of these five elements in the body 
produce a healthy life. 
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Man has gross physical body ( <^K~zl<*!and subtle physical body (S,g<Gll<*/!!The 
life force which is different from material energy derived from food, pervades the gross 
physical through the subtle physical. 
The food we eat has six tastes namely Sweet (-eqh<H*, Sour )Htqh<H*, Salt!)dh<H*,!
Bitter (jgh<H) , Pungent!)giIh<H*, Astringent (KuIh<H*/!
Each of them is a mixture of two basic elements. 
 -eqh<H!! .! l{<!!+  fQI 
 Htqh<H!! .! l{<!+kQ 
 dh<H! ! .! fQI!+ kQ 
 jgh<H!! .! gix<X!+!Ngibl< 
 KuIh<H! .! l{<!+ Ngibl< 
Panchboothas are the foundations for Three dosham Vaatham, Piththam, Kabam) 
which are the pillars that support our body structure 
 Vaayu Constitute Vaatham 
 Theyu Constitute Piththam 
 Appu Constitute Kabam 
Any alterations in the level of  mukkuttrams affects the normal functions of the 
body.  This is obvious from the verses, 
 ! lqgqEl<!GjxbqEl<!Ofib<osb<Bl<!F~OziI!
! ! utqLkzi!ou{<{qb!&e<X!
! ! ! ! ! ! .!kqVg<Gxt<!)lVf<K*!
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! The normal values of the mukkuttrams are in the ratio of  
 Vaatham : Piththam : Kabam= 1 : ½ : ¼ 
“upr<gqb!uikl<!lik<kqjv!obie<xqz<!
! kpr<gqb!hqk<kf<!ke<eqzjv!uisq!
! npr<Gr<!ghf<kiemr<gqOb!giOzicz<!
! hqxr<gqb!sQuIg<Gh<!hqs!ogie<Xlqz<jzOb” 
! ! ! ! .!G{uigml<!
! Alterations in the ratio, produces disease.  The signs and symptoms are produced 
according to the particular deranged kuttrams. 
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AZHAL KEEL VAAYU 
 In Siddha literature Azhal keel Vaayu comes under the topic of Vatha disease.  
Keel Vaayu is the general term that includes all kinds of joint disease (locomotor system) 
Description of the nomenclature 
 Azhal keel Vaayu  =  Azhal + keel + Vaayu 
 Azhal   = Piththam 
 Keel   = Joint 
 Vaayu   = Vaatham 
 Initially the joint is affected by the vitiated vaatham, kabam and piththam is 
accompanied later.  Also this is a disease of Pitha kaalam middle 1/3  of the life span. 
CLASSIFICATION: 
 In Siddha maruthuvam, keel vaayu is classified into ten types. 
1. Vali keel Vaayu 
2. Azhal keel vaayu 
3. Iyya keel vaayu 
4. Vali azhal keel vaayu 
5. Azhal vali keel vaayu 
6. Vali Iyya keel vaayu 
7. Azhal Iyya keel vaayu 
8. Iyya vali keel vaayu 
9. Iyya azhal keel vaayu 
10. Mukkutra keel vaayu. 
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Ofib<!uVl<!upq!)Aetiology): 
!giz!-bz<H!!.!Environmental Factors: 
 uikuIk<!ke!gizOlOki!oue<eqz<!
! ! lVUgqe<x!Neq!gx<gm!likl<!
! Nkjeh<!hsqObiM!giIk<kqjg!ke<eqz<!
! ! NmVOl!lx<x!likr<gt<!ke<eqz<!
! OhigOu!slqg<gqe<x!gizliGl<!
! ! ! ! .!B,gq!sqf<kil{q!
! The Vaatha disease will be precipiated in the months from Aani to karthigai (June 
to December) 
 hKlk<jkh<!h,g<g!jug<Gl<!hiElqgg<!giBl<!
! LKOueq!zqx<H!uqx<fQI!Lx<Xl<!.!gKole!
! ux<Xl<!ghlq0Gl<!uiBlqGl<!uip<lif<kIg<!
! Gx<x!fzqg<!Ogkqoke<!OxiK!
! ! ! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!
! In Muthuvenil kaalm, the increased solar radiation increases the evaporation of 
water content in the world, on the same time these similar action on the body produces 
increases absorption of mucous for digestion and develop the vitality of Vatha disease. 
So, this disease occurs predominantly in muthuvennil kaalam. 
d{Uujggt<!.!Diet: 
 “utq!kV!gib<gqpr<G!ujvuqzi!klqzz<!Ogijp!
! Htq!kbqI!Ohie<lqGg<G!Ljxbqzi!U{<c!Ogimz<!
! GtqIkV!utqbqx<!Oxgr<!Geqh<Hx!Uzuz<!oh{<cI!
! GtqkV!Lbg<gl<!ohx<OxiI!gcosbz<!gVuqbiliz</” 
      - shihkq!jgObM!
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! uik! Gx<xk<jk! lqjgh<hMk<kg<! %cb! gqpr<G! ujggt<,! GtqIs<sqjb!
kvg<%cb!hkiIk<kr<gt<!lqGkqbig!d{<{z<,!GtqIf<k!gix<xqz<!-Vk<kz<,!ljpbqz<!
fjekz<! heqg<gix<X! OlOz!uqPkz<! ljzh<hqvOksr<gtqz<! usqk<kz<!ntU!gmf<K!
dmZxU!ogit<tz<!lx<Xl<!hvl<hjvbqe<!giv{ligUl<!Okie<Xl</!
! okipqz<!ohX!jgh<Hg<giIk<kz<!KuIk<kz<!uqr<SgqER<OsiXl<!
! ! hjpbkil<!uvG!lx<jxh<!jhf<kqjebVf<kqeiZl<!
! wpqz<!ohxh<!hgZxr<gq!-vuqeqZxr<gikkiZl<!
! ! ljp!fqgi!GpzqeiOz!uikr<Ogi!hqg<Gr<giO{/!
! ! ! ! ! ! .!hvvis!Osgvl<!
! gsh<H,! KuIh<H! giIh<H! hkiIk<kr<gjt! lqGkqbig! d{<{z<! hjpb! OsiX!
uvG! kqj{! d{<{z<! hgzqz<! K~r<gq! -vU! uqpqk<kqVk<kz<! Ngqb!
giv{r<gtqeiZl<!uikl<!lqGhMl</!
hpg<g!upg<gr<gt<!)Habits) 
 oub<bqzqz<!fmg<jgbiZl<!lqgk<k{<{QI!Gcg<jgbiZl<!
! osb<bqjp!lgtqejvs<!OsIf<kEh!uqg<jgbiZl<!
! jhbOe!d{<jlbiZl<!higx<gib<!kqe<jgbiZl<!
! jkbOz!uikOvigl<!seqg<Gole<!xxqf<K!ogit<Ot/!
! ! ! ! ! ! ! .!OkjvbI!uigml<!
             Excessive walking in hot sun , excessive intake of bitter guard etc, may play a 
role disturb the normal functions of vaatham.    
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uikOfib<g<gie!-bz<H;!)!Characteristic features of Vaatha) 
  uikOl!gkqk<k!OhiK!uiBUolPl<Hr<!gi{<CI!
! ! uikOl!gkqk<k!OhiK!uiBuf<kqMR<!se<eq!Oki]l<!
! ! uikOl!gkqk<k!OhiK!uz<zMe<!olzqf<K!ogiz<Zl</!
! ! ! ! ! ! .!ngk<kqbI!sqgqs<si!vk<ei!kQhl</!
! uikl<! lqGl<OhiK! uiB! lqGl</! se<eqOkiml<! Ohie<x! hz! uqbikqgt<! uf<K!
OsVl<!dmz<!olzqBl</!
! ! uikuQX!ne<elqxr<giK!gMh<H{<mil<!u{<{L{<mil<!
! ! OliKgm<G!Ovigl<!SvL{<mi!lqVlZli!Lxr<gioke<Xl<!
! ! Ykiqb!uikleziG!fMg<gL{<mil<!ohiVt<gtbIf<k!
! ! kQokeOu!fvl<hqk<K!sf<Kgt<!OkiXr<gmg<Gf<!kqeLf<kiOe!
! ! ! ! ! ! .!OkjvbI!uigml<!
! uikl<! lqGl<OhiK! hsqbqe<jl,!dmz<! gMh<H,! Svl<,!-Vlz<,!dxg<glqe<jl,!
dmz<! fMg<gl<! fvl<Hk<ktIs<sq! sf<Kgt<! OkiXl<! Gjmkz<! Ohie<x! GxqG{r<gt<!
Okie<Xl</!
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Ofib<!uVl<!upq!.!Lg<Gx<x!hikqh<H!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ubK!d{U!
hpg<g!upg<gl<!
Sx<Xs<!S,pz<!
hqk<kl<!.!
sikgl<!
uikl<!.!
uqbiee<!.!
nhiee<!
ghl<!.!sf<kqgl<!
npz<!gQz<!uiB!
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Ofib<!GxqG{r<gt<!)Clinical Features) 
 hqk<k!gQz<uiB!ke<eix<!gQz<Lm<MuQr<gqs<!
! sqk<kI!osb<lVk<Kus<!sQIhmik!
! kg<gX!gib<s<sz<!g{<M!sizOu!kjekie!kf<Ok!
! olk<kX!sqgqs<js!ke<ekz<!ole<Olz<!fQg<Glh<hi!
! ! ! ! ! .!shihkq!jgObM!
! -K,!utqg<Gx<xl<!ke<eqjzbqz<!lqGf<Kt<tOhiK!npz<!Gx<xk<jkk<!K~{<mg<!
%cb!d{U,!osb<jg!Lkzqbux<xiz<!hqxg<Gl<!Ofibil</!!-f<Ofibqz<,!Lm<cgtqz<!
d{<miGl<!uQg<gl<!fiTg<Gfit<!ohVk<Kg<!ogi{<Om!uf<K,!lqGf<k!kQg<Gx<xk<kiz<!
gQz<gtqeqjmObBt<t! hjs! ux{<M! hjsbx<Xg<! gQz<! njsBl<! Ohiokz<zil<!
fm<jmBjmkZl<! #gZg<#! #gZg<#! oge<x! YI! yzq! d{<miuKlib<! -Vg<Gl</!!
sqzOujtgtqz<!gQZg<Gg<!gQz<!%c!ym<cg<ogi{<M!yV!gpqOhiz!lmg<g!LcbilOz!
fqe<X!uqMuKl<!d{<M/!!-f<Ofib<g<G!sqXSvLl<!uVl</!
! It is characterized by swelling of joints associated with severe pain and pyrexia.  
Since it is not quickly responding to medicine the prolongs medical care is said to be 
essential.  As piththa increases, kaba (mucuous) in the joint decrease and hence dryness 
occur.  So, during flexion of the joint crepitation is produced. 
Ofib<!g{qh<H!)Diagnosis):! !
Piniyari Muraimal is a method of diagnosing a disease (affecting the mankind) it 
is based upon three main principles; 
1. Poriyalarithal (Inspection) 
2. Pulanalarithal (Palpation) 
3. Vinaathal (Interrogation) 
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Physicians ‘ Pori’ and Pulan’ are used as tools for examing the ‘pori pulan’ of the 
patient.   
The above principles correspond to the methodology of 1.  Inspection, 2.  
Interrogation and 3. Palpation in modern medicine, in arriving  a clinical diagnosis of the 
disease. 
1.  Poriyalarithal (Inspection) 
 Pori is considered as the five senses of perception namely 
 1.  Nose  2.  Tongue 3. Eye  4.  Skin 5.  Ear 
 ‘Poriyalarithal’ is examining the ‘pori’ of the patient by the physician for 
diagnosing. 
2.  Pulanalarithal (Palpation) 
 ‘Pulan’ are five object of senses.  They are, 
 1.  Smell 2.  Taste  3. Vision 
 4.  Sensation to touch  5.  Hearing 
‘Pulanalarithal’ means examination of the ‘pulan’ of the patient by the physician 
for diagnosing purpose. 
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3.  Vinaathal (Interrogation) 
 Vinathal is gathering the informations regarding the history of diseases, its 
clinical features etc, from the patient or his close relatives who are taking care of him, 
when the patient is not in a position to speak or of the patient is a child. 
ntjugt<!(Logics) 
 Alavaigal are used in clinical diagnose of a disease. 
 ntju!gi{<mz<!gVkz<!djv!nhiul<!ohiVt<!yh<hioxe<hI!
! ntju!OlZl<!yzqH{<jl!jbkqgk<!Okicbz<!ohe!fie<!
! gtju!gi{<hI!njubqx<xqe<!OlZl<!njxuI!njuobz<zil<!
! ntju!gi{<mz<!gVkz,<!djv!we<Xl<!&e<xqzmr<gqMOl/!
! ! ! ! ! ! .!squsqk<kqbiI!ntju!w{</!7!
! Alavai is divided in to ten types, they are 
1. Observation - gi{<mz<! 6. Comparison - dhliel<!
2. Inference - gVkz<! 7. Inference by 
elimination 
- hiiqOs]l<!
3. Authority, 
Literature 
- djv! 8. Probability - sl<hul<!
4. Preception - nhiul<! 9. Tradition - JkQgl<!
5. Presumption - nVk<kh<hk<kq! 10. Natural Inference - -bz<H!
The above mentioned ‘ten alavaigal’ the main three alavaigal are: 
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1.  Kaandal (Inspection by Siddha Method) 
 Through ‘ kaandal’ the physician can directly see the patient hear the patients all 
the complaints and at length concludes a diagnosis. 
2.  Karuthal (Through Siddha Investigation) 
 Through Envagai thervu, Neerkuri and Neikuri, we can diagnose a disease by 
Karuthal. 
3.  Urai (Literature evidence of Siddha) 
 Comparative study of the signs and symptos of the patient with the reference 
books and come to a diagnosis. 
Ennvagai thervugal (Eight diagnostic tools) 
 Siddhars have developed a unqiue method of diagnosing the disease by “Enn 
vagai thervugal’ 
 “fic! <^hiqsl<!fi!fqxl<!olipq!uqpq!
! lzl<!&k<kvlqju!lVk<KuviBkl<” 
    .!Ofib<!fimz<!Ofib<!Lkz<!fimz!)Lkz<!higl<*!
! olb<g<Gxq!fqxl<!okieq!uqpq!fi!-Vlzl<!jgg<Gxq!
! ! ! ! .!OkjvbI!
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Hence the diagnosis is made by the following. 
1. Naadi (Pulse) 5. Mozhi (Voice) 
2. Sparisam (Sensation to Touh) 6. Vizhi (Eyes) 
3. Naa (Tongue) 7. Malam  (Faeces) 
4. Niram Colour 8. Moothiram (Urine) 
 The speciality of eight tools of diagnosis is mentioned in the following verses 
also. 
 “fQcb!uqpqbqeiZl<!fqe<x!fig<Gxqh<hqeiZl<!
! uicb!OleqbqeiZl<!lzoliv!fQiqeiZl<!
! S,cb!uqbikqke<jes<!Sgl<!ohx!nxqf<K!osiz<Oz”/!
!
! “kv{qBt<t!uqbikq!ke<je!bm<mir<gk<kiz<!
! kiexqb!Ou{<MuK!Obki!oue<eqz<!
! kqv{qbOkiI!fic!g{gt<!sk<kk<OkiM, 
! Okgk<kqeK!hiqsl<!uV{l<!fig<G, 
! Bqv{!lz!&k<kqvli!lqjug!otm<Ml<!
! bqkl<hmOukie<!hiIk<Kg<!Gxqh<Hr<!g{<M!
! hv{Vtiz<!ohiqObiIgt<!hikl<!Ohix<xqh<!
! h{<H!kuxilz<!h{<kR<!osb<uQOv” 
! ! ! ! ! .!ngk<kqbI!G{uigml<!
!
!
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! “okiGg<gZx<X!nm<muqjkh<!hiQm<js!ke<jek<!
! Kzg<gLxl<!h{<ckOv!oktquigh<!
! hGg<giqb!ficjb!fQ!hck<Kh<!hiVh<!
! hgIgqe<x!uiIk<jkjbh<!hiI!fijuh<!hiV, 
! uGg<giqb!Okgolek<!okim<Mh<!hiV, 
! utlie!siQvk<kqe<!fqxk<jkh<!hiV, 
! sgqg<giqb!lzk<jkh<!hiI!szk<jkh<!hiV!
! siIf<k!uqpqkjeh<!hiIk<K!oktquib<g<!giO{/” 
! ! ! ! ! .!!ngk<kqbI!juk<kqb!uz<zikq!.!711!
Azhal Keel Vaayu in relation with Ennvagai thervugal 
1.  Naadi (Pulse) 
 dmzqz<! dbqI! kiqk<kqVh<hkx<Gg<! giv{lie! sk<kq! wKOui! nKOu! kiK!
nz<zK!fic!weh<hMl</!
! “fic!we<xiz<!ficbz<z,!fvl<hqz<!kiOe!
! fzligk<!Kcg<gqe<x!KckiElz<z!
! fic!we<xiz<!uik!hqk<k!sqOzx<heLlz<z!
! fic!wPhk<kQvibqvf<!kiElz<z!
! fic!we<xiz<!n{<m!Ohv{<molz<zil<!
! fic!wPujgk<!Okix<xk<Kt<tib<!fqe<x!
! ficbKbi!vib<f<K!hiIk<kivieiz<!
! ficBXl<!ohiVt<!okiqf<K!fiM!uiOv”/!
! ! ! ! ! ! .!hkqoe{<!sqk<kI!skg!fic!F~z<!
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 Naadi is responsible for the existence of life and can be felt one inch proximal to 
the wrist on the radial side by means of palpation with the timps of index, middle and 
ring fingers corresponding vaatham, piththam and kabam respectively. 
 The three humours vaatham, piththam and kabam exists in the ratio 1: ½ : ¼ 
normally.  Derangement in these ratios leads to various disease entities. 
 The three “Uyir thathukal” are formed by the combination of three nadigal with 
three vaayu. 
 a)    Edakalai  + Abaanan =  Vaatham 
 b)   Pinkalai  + Piranan =  Piththam 
 c)   Suzhumunai + Samanan =  Kabam 
In Azhal Keel Vaayu the following types of naadi can be seen commonly. 
They are, 
a) Vaatha piththam 
b) Vaatha kabam 
c) Pithatha vaatham 
d) Pithatha kabam 
e) Kaba vaatham 
II.  Sparism 
In case of Azhal Keel Vaayu mild warmth noticed over the affected joint. 
III.  Naa 
 In case of Azhal Keel Vaayu no abnormality is seen in Naa 
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IV. Niram 
 In case of Azhal Keel Vaayu no abnormality is seen in Niram 
V. Mozhi 
 In case of Azhal Keel Vaayu no abnormality was ruled out. 
VI. Vizhi 
 In case of Azhal Keel Vaayu no abnormality is seen in vizhi. 
VII. Malam 
 In case of Azhal Keel Vaayu constipation was reported in some cases. 
VIII. Moothiram 
 Collection of urine for the determination of Neerkuri and Neikuri, a special 
diagnotic method. 
Neerkuri and Neikuri 
 “nVf<K!lixqvkLl<!nuqOvilkib<!
! n0gz!nzuIkz<!ngizU,e<!kuqIf<kpx<!
! Gx<xt!uVf<kq!dxr<gq!jugjx!
! Ncg<!gzsk<!kiuqOb!giKohb<!
! OkiV!L%Ik<kg<!gjvGm<!hMfQIqe<!
! fqxg<Gxq!ofb<g<Gxq!fqVlqk<kz<!gmOe”/!
! ! ! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!
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Prior to the day of urnine examination the patient is instructed to take a balanced 
diet and quantities of food must be proportionate to his routine in take.  The patient could 
have no disturbed sleep.  After wake up in the morning, the first urine voided is collected 
in  a clear wide mouthed glass dish or Hina Clay container and is subjected to analysis of 
“neerkuri and neikuri” with in one and  a half an hour.  Then, neerkuri is to be found out 
by Neerkuri. 
 “uf<k!fQIg<giq!jbjm!l{l<!Fjv!wR<soze<!
! jxf<kqb!Ztju!bjxGK!LjxOb” 
! ! ! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!
Voided urine has the following characters 
 1.  Niram -  Colouration 
 2.  Edai - Specific gravity 
 3.  Manam - Smell 
 4.  Nurai - Frothy nature 
 5.  Enjal - Quantity of urine voided 
 Apart from these, the frequency of urination, abonormal constituents, such as 
sugar, protein, presence of blood, pus, renal calculus crystals also be to found out. 
 In Azhal Keel Vaayu patient straw or hay coloured urine is noticed.   
Neikuri: 
 The speciality of neikuri is stated in the following verse. 
! “Jbg<Gxq!ogiMum!ui{qp!zlIf<OkiI!
! jgg<Gxq!okiqk<k!fr<gmUjtk<!Kkqk<Ok!
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! olb<g<Gxq!fqxf<okieq!uqpq!fiuqVlzl<!
! jgg<Gxq!LpuK~!dr<gx<xiI!kl<lqEl<!
! ohib<g<Gxq!olb<g<Gxq!HgZol!uIg<Gl<!
! ofb<g<Gxq!bkje!bqf<fQ{qzk<K!jvh<hOhil”.<!
! ! ! ! .!sqk<k!lVk<Ku!Ofib<!fimz<!Ofib<!Lkeimz<!kqvm<M!
 The Process of dropped gingely oil indication 
! “fqg<Gxqg<!Gjvk<k!fqVli!{!fQiqx<!
! sqxg<g!ou{<o{b<!ObiI!sqXKtq!fMuqMk<!
! oke<xk<!kqxf<okizq!Obgikjlk<kkq!
! eqe<xkqujz!Ohil<!ofxquqpqbxqbUl<!
! ose<xK!HgZ<!osb<kqjb!B{Ov” 
    - sqk<k!lVk<Ku!Ofib<!fimz<!Ofib<!Lkeimz<!kqvm<M!
 The collected specimen as said above is to be analysed by following method.  The 
specimen is kept open in a glass dish or hina clay container.  It is to be examined under 
direct sunlight, without any shaking of the vessel.  Then add one drop of gingely oil by at 
a distance of ½” or ¾” height observe cleanly the direction it spreads with in few 
minutes, and conclude the diagnosis as follows. 
! “nvoue!fQ{<ce!n0Ok!uikl<!
! Npq!Ohiz<!hvuqe<!n0Ok!hqk<kl<!
! Lk<okik<K!fqx<gqe<!olipQuoke<!ghOl!
! Nvuqz<!NpqBl<!Npqbqz<!nvUl<!
! nvuqz<!Lk<Kl<!Npqbqz<!Lk<Kl<”. 
! ! ! ! .!sqk<k!lVk<Ku!Ofib<!fimz<!Ofib<!Lkeimz<!kqvm<M!
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Paruvakaalm (Seasonal Variation): 
Sl.No Kalam Kuttram State of Kuttram Suvai 
1. Kaar Kaalam  
(Aavani – Puratasi) 
(Aug 16 – Oct 15) 
Vaatham↑↑ 
Piththam↑ 
Vettrunilai Valarchi 
Thannilai Valarch 
Enippu 
Pulippu 
Uppu 
2. Koothir kaalam 
(Iypasi – Karthigai) 
(Oct 16 – Dec 15) 
Vaatham (-) 
Piththam ↑↑ 
Thannilai Adaithal 
Vettrunilai Valarchi 
Enippu 
Kaippu 
Thuvarppu 
3. Munpanikaalam 
(Markazhi – Thai) 
(Dec 19 – Feb 15) 
Piththam (-) Thannilai Adaithal Enippu 
Pulippu 
Uppu 
4. Pinpanikaalam 
(Masi – Panguni) 
(Feb 16 – Apr 15) 
Kabam ↑ Thanniklai Valarchi Enippu 
Pulippu 
Thuvarppu 
5. Elevenil kaalam 
(Chithirai – Vaikasi) 
(Apr 16 – Jun 15) 
Kabam ↑↑ Vetrunilai Valarchi Kaippu 
Karppu 
Thuvarppu 
6. Mudhuvenil kaalam 
(Aani – Aadi) 
(Jun 16 – Aug 15) 
Vaatham ↑ 
Kabam (-) 
Thannilai Valarchi 
Thannilai Adaithal 
Enippu 
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Thinai (Geographical Distribution) 
 It is divided in to five types. 
1.  Kurinji : Mountain regions and surroundings 
2.  Mullai : Forest regions and surroundings 
3.  Marutham : Cultivating regions and surroundings 
4.  Neithal : Sea and coastal region 
5.  Palai : Desert land only 
Geographical Distribution play a vital role in altering Mukkutrams. Vaatha 
disease is prominent in Mullai and Naithal thinai. 
Udal Kattugal 
 Our body consists of seven udal kattugal.  It gives strength and structure to our 
body. 
Sl.No Udal 
kattugal 
Functions 
1. Saaram It gives strength to the body and mind 
2. Senneer Saram after absorption is converted into senneer.  It is 
responsible for knowledge strength, boldness and healthy 
complexion. 
3. Oon Gives structure and shape to the body and is responsible for 
the movements of the body. 
4. Kozhuppu Lubricates the organs and proceed on its own works. 
5. Enbu Protects the vital organs and used for  movements and 
nominates body structure 
6. Moolai Present inside the bones and it gives strength and maintains 
the normal condition of the bone. 
7. Sukkilam 
(or) 
Suronitham 
Responsible for the reproductive function of species. 
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Sl.No Udal 
Kattugal 
Increased Conditions Decreased Conditions 
1. Saaram Leads to disease identical to the 
increase in kapha like loss of 
appetite, excessive salivation 
Loss of weight, tiredness, 
dryness of skin, laziness, 
diminished activity of the 
sense organs 
2. Senneer Boils and tumous in different 
parts of the body, splenomegaly 
Colic pain, increased blood 
pressure, reddish eye and skin, 
jaundice, leprosy, haematuria 
etc. 
Tiredness, Lassitude, 
anaemia 
3. Oon Tumours or extra growth 
around the neck, face, 
abdomen, thigh, genitalia etc. 
Muscle wasting 
4. Kozhuppu Identical to that of increased 
oon associated with dysponea 
and loss of activity 
Pain 
5. Enbu Strong bones and teeth Weak bones, teeth, nails and 
hairs 
6. Moolai Heaviness, swollen eyes, 
swollen phalanges, oliguria and 
non – healing ulcers 
Ostoporosis and shunken 
eyes 
7. Sukkilam 
(or) 
Suronitham 
Increased sexual activity and 
signs identical to urinary calculi
Failure to reproduce, pain in 
genitalia etc. 
 In the case of Azhal Keel Vaayu out seven Udalkattugal Saaram, Kozhuppu, 
Moolai, Enbu are commonly affected. 
 Saaram : Weakness, Pain in Knee joints 
 Kozhuppu : Morning Stiffness occurs in affected Knee joints 
 Enbu  : Pain occuring in affected knee joints, crepetations 
 Moolai  : Osteo Athritis in Knee Joints 
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Mukkutram 
 Human body is influenced by Mukkuttrams (ie) Vaatham, Piththam and Kabam.  
They are responsible for normal physiological condition of the body. 
Vaatham 
uikl<!
uikl<!uiPlqml<;!
 nhiee<!
 lzl<!
 -mgjz!
 df<kqbqe<!gQp<!&zl<!
 gilg<ogic!
 -Mh<H!
 wZl<H!
 Okiz<!
 fvl<Hg<!%m<ml<!
 gQz<gt<!
 lbqIg<giz<!
 De<!
uikk<kqe<!-bx<jg!h{<H;!
2/ Dg<g!L{<mig<gz<!
3/ &s<S!uqmz<!uir<gz<!
4/ leolipq!olb<gTg<Gs<!osbjzk<kiz<!
5/ lzl<!Lkzqb!hkqeie<G!uqjvUgjt!outqh<hMk<kz<!
6/ sivl<!Lkzqb!WP!dmx<gm<Mgm<Gl<!yk<k!fqgp<s<sqjbk<!kvz<!
7/ Jl<ohixqgm<G!ue<jljbg<!ogiMk<kz</!
!
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uikl<!.!dmzqz<!osb<okipqz<;!
2/ dmz<Ofikz<!
3/ Gk<kz<!
4/ hqtk<kz<!Ohix<gi{z<!
5/ fvl<H!Lkzqb!Ge<xz<!
6/ fMg<gz<!
7/ -Xg<glikz<!
8/ fQIh<hjsbqe<jl!
9/ njsk<kz<!
:/ -jtk<kz<!
21/ Gjms<sz<!
22/ kc!Lkzqbux<xiz<!nch<hm<mK!Ohie<x!Oukje!
23/ jg!nz<zK!giz<!-ml<!uqm<Mh<!ohbIkz<!)&m<M!fPuz<*!
24/ dXh<Hk<!ktIs<sq!
25/ dXh<Hgt<!okipqz<!Hiqbilz<!lvl<!Ohizg<gqmk<kz<!
26/ lzl<,!sqXfQI!Lkzqbe!kQb<kz<!nz<zK!njmhMkz<!
27/ fQIOum<jg!
28/ og{<jmg<giz<,!okijm!Lkzqbe!ofiXr<gqh<!OhiuK!Ohizk<Okie<xz</!
29/ wZl<Hg<Gt<!Kjth<hK!Ohie<x!d{Is<sq!
2:/ lbqIg<%s<!osxqkz<!
31/ jg!giz<gjt!lmg<gUl<!fQm<mUl<!-bzikhc!osb<kz<!
32/ ws<SjuBl<!KuIh<hib<!-Vk<kz<!nz<zK!KuIhig!uib<!fQVxz<!
33/ Okiz<,!g{<,!lzl<,!fQI!Lkzqbe!gXk<Kg<!gi{z</!
!
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uikk<kqe<!G{l<;!
 uxm<sq!(dry) 
 GtqIs<sq!(Cold) 
 n[k<Kul<!(Subtle) 
 gcel<!(Rough) 
 njskz<!(Unstable) 
 -zG!(Light) 
uikk<kqe<!ujggt<;!
2/ hqvi{e<;!
&s<S!uqMkZl<!uir<GkZl<!osb<Bl<!
3/ nhiee<;!
lzszk<jk!gQp<!Ofig<gq!kt<Tl<!
4/ uqbiee<;!
dmzqZt<t!njsBl<! ohiVt<! njsbih<! ohiVt<! we<El<! -v{<cZlqVf<K!
dXh<Hgjt!fQm<mUl<!lmg<gUl<!osb<Bl</!
5/ dkiee<;!
uif<kqjb!wps<osb<Bl</!
 Vaatham is a kinetic energy, which influences all movements. 
 Vaatham is located in the abanan, idakalai, faees, spermatic cord, iliac bone, skin, 
nerves, joints, hair folicless, muscles, bone, ear and thigh. 
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Sl.No Name Locations Physiologic functions 
1. Piranan Heart and Lower and 
Upper Respiratory 
Tracts 
Controls knowledge, mind and 
five objects of sense useful for 
breathing 
2. Abanan Lower abdomen and 
extremities 
Responsible for urination, expels 
faeces and foetus, dioscharge 
sperm and menstruation. 
3. Viyanan Mainly at heart Responsible for movement of all 
parts of the body and sued to fell 
the sensation 
4. Uthanan Chest Responsible for vomiting cough, 
hiccough, sneezing 
5. Samanan Stomach Aids for proper digestion.  It 
controls the activity of other 
vaayus 
6. Naagan Eyes Responsible for opening and 
closing of the eyes 
7. Koorman  Heart and Eyes Responsible for vision and 
yawning and controls lacrimation 
8. Kirukaran Throat Responsible for salivation nasal 
secretion and appetite 
9. Thevathathan Eruvai & Karuvai For laziness, sleeping and anger 
defecation, reproduction 
10. Thananjeyan Nose Responsible for bloating of the 
body after death.  It escapes on the 
third day after death through the 
cranium when it bursts. 
In the case of Azhal Keel Vaayu 
1.  Abanan  - Habitual constipation 
2.  Viyanan  - Difficulty in movements of the knee joint 
3.  Samanan  - Due to other vaayus it is affected 
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Piththam 
 Piththam is responsible for all the transformation.  Piththam is located in urinary 
bladder, heart, head, umbilicus, abdomen, blood, sweat, skin and eye. 
 Piththam is classified into 5 types.  They are, 
 1.  Anala Piththam  - Responsible for digestion of food 
 2.  Ranjaga Piththam  - Responsible for colour of blood 
 3.  Sathagam   - Located in heart and is responsible for  
normal activities of the body. 
 4.  Alosagam   - Responsible for normal vision 
 5.  Prasagam   - Responsible for the complexion of skin. 
 In case of Azhal Keel Vaayu 
1.  Sathagam - Difficulty in walking, climbing upstairs,  squatting, sitting cross 
legged (Daily Activities). 
Kabam 
 Stabilizes, maintains and lubricates all movements. 
 Kabam is foud in samanan, semen, brain, head, tongue, nose, bones, bone 
marrow, fat, nerves, chest, blood, large intestine, eye,s tomach and pancreas. 
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Kabam is classified in to 5 types, they are 
1. Avalambagam : Heart is the center for avalambagam.  It 
controls all other forms of kabam 
2. Kilethagam : Stomach is the center for kilethagam.  It 
give moisture and softness to the ingested 
food and helps for digestion 
3 
 
Bothagam : Tongue is the center for Bothagam and it is 
responsible for the sense of taste 
4. Dharpagam : Head is the center for Dharpagam.  It gives 
cooling effect to eyes 
5. Santhigam : It lies in the joints and is responsible for the 
locomotive action of movable bony joints. 
In case of Azhal Keel Vaayu, 
Santhigam         :   Pain, tenderness in the knee joints,  
Cripitations present  
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Humor Increase Decrease 
Vaatham Distended abdomen, 
Constipation,  
Weakness,  
Insomnia,  
Tremors  
Breathlessness,  
Blackish discoloration 
Body pain,  
Feeble Voice,  
Syncope, 
Diminished capability of 
brain 
Piththam Yellowish disoloration of 
eyes, skin, urine and 
motion 
Polyphagia, 
Polydypsia, 
Burning sensation all over 
the body, 
Sleeplessness 
Cold, 
Pallor, 
Decreased appetite  
Symptoms associated with 
growth of kabam 
Kabam Loss of appetite, 
Excessive salivation, 
Heaviness, 
Dyspnoea, 
Excessive sleeping, 
Whiteness, 
Diminished activity 
Prominence of bone edges, 
Dry cough, 
Lighness, 
Profuse sweating,  
Palpitation,  
Giddiness, 
Dryness of joints 
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Relation between Suvai, Panjabootha and Mukkutram 
Sl.No Suvai Panjabootha Mukkutram 
1. Enippu 
(Sweet) 
Piruthivi + Appu Kapha   ↑ 
Vatha    ↓ (-) 
Pitha     ↓ (-) 
2. Pulippu (Sour) Piruthivi + Theyu Kapha    ↑ 
Pitha      ↑ 
Vatha     ↓ (-) 
3. Uppu (Salty) Appu + Theyu Kapha    ↑ 
Pitha      ↑ 
Vatha     ↓ (-) 
4. Kaippu 
(Bitter) 
Vaayu + Space Vatha     ↑ 
Kapha    ↓ (-) 
Pitha      ↓ (-) 
5. Karppu 
(Pungent) 
Vaayu + Theyu Vatha     ↑ 
Pitha      ↑ 
Kapha    ↓ (-) 
6. Thuvarppu 
(Astringent) 
Piruthivi + Vaayu Vatha     ↑ 
Kapha    ↓ (-) 
Pitha      ↓ (-) 
↑ - Valarchi 
↓ - Samappaduththal 
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Lg<Gx<x!OuXhiM!)pathophysiology): 
 Vaatham is mainly responsible for proper locomotor functions.  Bones and joints 
are considered be the vatha place. 
 In Azhal keel vaayu, vaatha is the first vitiated which has an impact over Vianan 
and Abaanan (among the types of Vaatham) 
 Deranged Vianan leads to pain and difficulty in movements while Abaanan leads 
to constipation. 
 Along with Vaatham, Kabam is altered from its normal proportion, Santhegam is 
affected and this leads to abnormality in joints movements. 
 Atlast piththam is altered with affection in Saathagam as it hinders the desire in 
locomotion. 
giz!fqjzgtqz<!Lg<Gx<xl<!)Three doshams in seasonal variation) 
! ke<eqjz!utIs<sq! Oux<Xfqjz!
utIs<sq!
ke<eqjz!
njmkz<!
uikl<! LKOueqz<! giIgizl<! %kqIgizl<!
hqk<kl<! giIgizl<! %kqIgizl<! Le<heq!
ghl<! hqe<heq! -tOueqz<! LKOueqz<!
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! Vaatham vitiates during muthuvenil ie., during Summer, the environment is hot it 
leads to dryness, similarly the body is affected by excessive heat and loses its energy 
through perspiration and the digestion is impaired. 
 So, in Azhal keel vaayu the disease shows its exacerbation during Muthuvenil 
kalam. 
Udal Vanmai – Body Immunity 
 The Udal Vanmai is classified in to 3 types.  They are, 
1. Iyarkkai Vanmai 
2. Seyarkai Vanmai 
3. Kaala Vanmai 
1.  Iyarkkai Vanmai : 
 Natural immunity of the body itself by birth 
2.  Seyarkai Vanmai: 
 Improving the health by intake of nutritious food materials, activities and 
medicines. 
3.  Kaala Vanmai: 
 Development of immunity according to age and environment 
 Seyarkai vanmai often individual is affected in Azhal Keel Vaayu patients 
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Gnanenthiriyam. 
 Gnanenthiriyam are Mei, Vaai, Kan, Mooku and Sevi 
1.  Mei    : Feels all types of sensation 
2.  Vai    : For recognize taste 
3.  Kann   : Meant for vision 
4.  Mooku   : For recognize smell 
5.  Sevi   : For hearing 
In case of Azhal Keel Vaayu no abnormalities are seen 
Kanmenthriyam 
 Kanmenthriyam are kai, kaal, vaai, eruvaai and karuvai 
1.  Kai    : Majority of normal works done by hands 
2.  Kaal   : For Walking 
3.  Vaai   : For Speaking 
4.  Eruvaai   : For defaecation 
5.  Karuvaai   : For reproduction 
In case of Azhal Keel Vaayu “Kaal” affected.  
Ofib<!fqkiel<!)Differential diagnosis): 
 Azhal keel vaayu is differentiated from other types of keel vaayu as follows: 
1. Vali Keel Vaayu: 
 It is characterized by excruciating pain and swelling involved in toes, knee joints, 
hip joints, elbow joints, shoulder joints and associated with systemic disturbances like 
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dryness of mouth, pyrexia, headache, palpitation, constipation and sweating.  In advanced 
cases it may affect the heart and produce “Thamaraga Vaayu”. 
2. Iya Keel Vaayu: 
 It is characteruized by severe pain in the joints associated with emaciation of the 
body, anorexia, insomnia, cough, hiccough, vomiting, anamemia and dropsy.  The 
common sites are spinal cord, hip joint and knee joint. 
3.  Vali Iya keel Vaayu: 
 It is characterized by pain in the joints associated with effusions of joint fluid and 
selling, restricted joint movements, pyrexia, fainting, insomnia, especially in knee joint 
asvmmetrically, lymphadenopathy, generalized malaise, atrophy of the affected limb etc., 
The affected joint looks like “Fox’s Head”. 
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Line of Treatment 
 In Siddha system, the main aim of the treatment is to cure Udarpini (due to 
Mukkuttram) and Manapini (due to changes in Mukkunam).  Treatment is not only for 
perfect healing but also for the prevention and rejuvenation. 
Thiruvalluvar says about physicians duty, study the disease, study the cause, seek 
subsiding ways and do what is proper and effective. 
“Ofib<!fic!Ofib<!Lkz<!fic!nK!k{qg<Gl<!
uib<!fic!uib<h<hs<!osbz<”/!
“dx<tietUl<!hq{qbtUr<!gizLl<!
gx<xie<!gVkqs<!osbz<” 
! ! ! ! ! ! ! .!kqVg<Gxt<!
! So it is essential to know the disease, the aetiology, the nature of the patient, 
severity of the illness, the seasons and the time of occurrence must be observed clearly. 
 Line of treatment is as follows: 
 Kaappu (prevention) 
 Neekkam (Treatment) 
 Niraivu (Retoration) 
Kaappu: (Prevention) 
 As per Siddha system even during the time of conception the vinaipayan is 
transferred into the fertilized embryo, which is aetilogy for certain diseases may be cured 
not only by medicines but by teaching the following habits. 
 40
1. Teaching good moral habits. 
2. Avoid Stress and strain. 
3. Taking purgatives once in 6 months. 
4. Always have good mental thoughts by doing meditation. 
5. Yoga 
! All the patients were also avised to follow Siddhars preventive measures which 
would give immortality of body and soul, quoted in Pathartha Guna Chinthamani as 
follows. 
 “kq{<{!lqv{<Mt<ot!sqg<g!umg<gilx<!
! oh{<{qe<hi!ozie<jxh<!ohVg<gilz<!.!d{<[r<giz<!
! fQiSVg<gq!OliI!ohVg<gq,!ofb<BVg<gq!B{<huIkl<!
! OhVjvg<gqx<!OhiOl!hq{q” 
!
! “hiZ{<Ohil<;!w{<o{b<ohxqe<!ouf<fQiqx<!Gtqh<Ohil< ;!
! hgx<H{Ovil<;!hgx<XbqOzil< ;!hObikvL!&k<k!
! WzR<OsI!GpzqbOvi!ctoubqZl<!uqVh<Ohil<!
! -v{<mmg<Ogil< ;!ye<jxuqOmil< ;!-mK!jgbqx<!hMh<Ohil<!
! &zR<OsI!gxq!FgOvil<!&k<k!kbqI!d{<Ohil< ;!
! Lkeitqx<!sjlk<kgxq!bLokeqE!lVf<Okil< ;!
! Rizf<kie<!uf<kqcEl<!hsqk<okipqb!U{<O{il<!
! fleiig<gqr<!OgKgju!filqVg<G!lqmk<Ok/” 
!
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! “d{<hkqV!ohiPokipqb!&e<X!ohiPK{<O{il< ;!
! dxr<Gukq!viouipqbh<!hgZxg<gR<!osb<Ouil< ;!
! oh{<!gmjlk<!kqr<gTg<OgiI!gize<xq!lVOuil< ;!
! ohVf<kig!olMk<kqcEl<!ohbIk<K!.!fQvVf<Okil<” 
! l{<!hvU!gqpr<Ggtqx<!gVj{bqe<xq!HsqObil; <!
! uijpbqtl<!hqR<osipqbg<!geqbf<kz<!osb<Ouil< ; 
 f{<Hohx!U{<mhqe<H!GxfjmBr<!ogit<Ouil<!
! fleiIg<gqr<!OgKgju!filqVg<Glqmk<Ok”/!
!
! “NX!kqr<gm<!ogiV!kmju!ule!lVf<!kbqz<Ouil<!
! nmI!fie<G!lkqg<ogiVgix<!OhkqBjx!FgIOuil<!
! OkXlkq!obie<xjvg<OgiI!kvfsqbl<!ohXOuil<!
! kqr<gtjvg<!gqv{<MkvR<!sutuqVh<HXOuil<!
! uQXsKI!fim<ogiVgiz<!ofb<ogiVgi!zqMOuil<!
! fiXgf<kl<!Hm<lqju!fMfqsqbqe<!LgOvil<!
! fleiIg<gqr<!OgKgju!filqVg<G!lqmk<Ok!
!
! “hgk<okiPg<G!likvsr<!gvf<Kjmh<h!lqju!f<K~m<!
! hmofVr<Ogil< ;!kQh!jlf<kI!lvfqpzqz<!usqObil< ;!
! Sgh<H{Is<sq!bsehg!ek<kV{R<!osb<Obil< ;!
! KR<sZ{!uqVlzR<js!ObiglPg<!gijm!
! uGh<ohMg<gqx<!sqf<Kgs!lqju!lijz!uqVh<Ohil<!
! ux<szf<okb<!ul<hqKIsx<!Gvju!uqm!lim<Omil<!
! fgs<szL!Ljts<szLf<!okxqg<Glqm!l[Ogil<!
! fleiIg<gqr<!OgKgju!filqVg<G!lqmk<Ok” 
! ! ! ! ! ! .!!hkiIk<k!G{!sqf<kil{q!
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Neekkam (Treatment) 
 The aim of treatment is based on  
a) To bring the three Thodams in to normal equilibrium state. 
b) To treat the patient according to symptoms, by internal medicine 
For normalizing three Thodams, 
“uqOvsek<kiz<!uikl<!kiPl<!
ulek<kiz<!hqk<kl<!kiPl<!
fsqb!nR<sek<kiz<!ghl<!kiPl</” 
Here Azhal Keel Vaayu, Vaatha humor is deranged mainly.  Administration of 
laxatives or purgatives to the patients brings the vitiate vatha into normal.   
Treatment: 
 The treatment in Siddha system includes not only the removal of signs and 
symptoms of a disease but also in total uprootment of the diseases. 
 This is achieved by normalizing the vitiated Mukkuttrams there by retaining 
body’s natural health.    
 In Azhal keel vaayu, the deranged vaatham is brought to its normal state by 
purgation (uqOvsel<*/!
! “uqOvsek<kiz<!uikf<kiPl</” 
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• 10 ml of Sithathi ennai was  given with Sombu kudineer early morning with 
empty stomach -  Firstday only 
• Mirudharsingi chunnam : 65 mg twice- a –day given with ghee after taking food. 
• Poochu Ennai : external application over the affected joint. 
hk<kqbl<!)Dietary restrictions) 
! -s<sihk<kqbk<kqz<!fQg<Gl<!ohiVt<gt<!
! gMG!fx<xqzk<!ok{<o{b<!%p<hi{<mr<gt<!gmjz!
! uMu!kigqb!okr<Gli!uVg<jg!fx<gibl<!
! lcuq!zikout<Tt<tqogit<!Hjgbqjz!lKoh{<!
! -mX!higOzi!mgk<kq!fQg<gqmzqs<!sihk<kqbl<!
! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!
! gMG,! wt<ofb<,! gz<bi{! h,seqg<gib<,! gt<,! gmjz,! Okr<gib<,! lir<gib< ,!
hzi,!gibl< ,!dt<tqh<h,{<M,!ogit< ,!Hjgbqjz,!oh{<gt<!OsIg<jg,!higz<,!ngk<kq!
-jugjt!-s<sihk<kqbk<kqz<!fQg<g!Ou{<Ml</!
! “HtqKuI!uqR<Sl<!gxqbiz<!H,iqg<Gl<!uikl<” 
 Htqh<H,!KuIh<H!SjuBt<t!d{U!ujggjt!fQg<g!Ou{<Ml</!
Implementation of special medicine methods to the Needy (Sirappu Maruthuva Parigara 
Muraigal – (Yogasanas and Thokkanam)  
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MODERN ASPECTS 
Osteo Arthritis 
Introduction 
 Osteoarthritis can be defined as a gradual loss of articular cartilage, combined 
with thickening of the subchondral bone; bony outgrowth (osteophytes) at joint margins; 
and mild, chronic nonspecific synovial inflammation. 
Epidemiology: 
 Osteoarthritis is by far the most common joint disorder throughout the world, and 
is one of the leading causes of disability in the elderly. 
 Although the disease commonly affects the cervical and lumbar spine, most 
epidemiologic studies report that it has a predilection for weight – bearing joints in the 
leg and certain joints in the hand. 
 The prevalence of Osteoarthritis in all joints correlates strikingly with age.  One – 
third of people aged 65 years and older have knee Osteoarthritis that is evident by 
radiograph.  Before the age of 50, men are more likely to have Osteoarthritis than 
women, but after age 50, it is women who are more likely to be affected. 
 Osteoarthritis is already one of the ten most disabling diseases in developed 
countries. 
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 Farming 1-9 years increases the risk of osteoarthritis 4 times, farming 10 or more 
years increases the risk 9 times. 
 Worldwide estimates are that 10% of men and 18.0% of women aged over 60 
years have symptomatic osteoarthritis. 
 80% of those with osteoarthritis will have limitations in movement, and 25% 
cannot perform their major daily activities of life. 
Local Factors: 
Excess Weight : 
 Population – based studies of osteoarthritis consistenly have shown that 
overweight people are at greater risk of developing knee osteoarthritis than average – 
weight controls. 
 Obese women are four to five times more likely to have knee osteoarthritis than 
persons of average weight.  Studies suggest that obese people with knee osteoarthritis are 
at greater risk than thinner people for disease progression.  Weight reduction is likely to 
lesson the symptoms of knee Osteoarthritis. 
 Although the association with body weight is not as strong for hip osteoarthritis as 
it is for knee osteoarthritis, overweight people appear to be at increased risk of 
osteoarthritis in all weight bearing joints, including hip osteoarthritis.  Surprisingly, there 
is also a positive association between obesity is a systemic risk factor for osteo arthritis. 
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Injury and Occupation: 
 Major acute knee injuries, including cruciate ligament and meniscal tears, are 
common causes of knee osteo arthritis.  Osteoarthritic changes have been reported in up 
to 89% of people after meniscectomy.  Most people who have experienced complete 
anterior curciate ligament rupture will develop knee osteo arthritis. 
 Osteo arthritis is associated with a variety of sport activities including running 
(hip osteoarthritis), Soccer playing (knee and hip osteoarthritis), and Football playing 
(knee osteoarthritis). 
Pathogenesis 
Normal Articular Cartilage 
 Normal cartilage has two main components.  One is the extracellular matrix, 
which is rich in collagens (mainly types II, IX and XI) and proteoglycans 9 mainly 
aggrecan. 
 Aggrecan is a central core protein bearing numerous glycosaminoglycans chains 
of chondroitin sulfate and keratan sulfate, all capable of retaining water. 
             The second component consists of isolated chondrocytes, which lie in the matrix. 
The matrix components are responsible for the tensile strength and resistance to 
mechanical loading of the articular cartilage. 
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Passage of Normal Cartilage to Aging cartilage  
   Several structural and biochemical changes involving the non collagenous component 
of the matrix occur during aging. These changes alter biochemical properties of the 
cartilage that are essential for the distribution of forces in the weight-bearing zone. 
    Glycosaminoglycans are modified qualitatively; they become shorter as the cartilage 
ages. The concentration of type 6 keratan sulfate increases during aging, to the detriment 
of type 4 keratan sulfate. 
     These quantitative and qualitative change in proteoglycan reduce the capacity of the 
molecules to retain water. Thus, aging cartilage contains less water, which alters the 
biochemical properties of the cartilage. Fissures that develop aging are due mainly to 
stress fractures of the collangen network. 
Osteoarthritic joints 
Osteoarthritic joints have abnormal cartilage and bone, with synovial and capsular 
lesions. 
 Macroscopically, the most characteristic elements are  
 Reduced joints space. 
 Formation of osteophytes (protrusion of bone and cartilage) mostly at the margins 
joints. 
 Sclerosis of the subchondral bone  
 48
These changes are the result of several histologic phases  
Phase 1: edema and microcracks. 
 The first recognizable change osteoarthritis is edema of the extracellualr matrix, 
principally in the intermediate layer. The cartilage loses its smooth aspect, and 
microcracks appear. There is a focal loss of chondrocyting with areas of chondrocute 
proliferation. 
Phase 2: fissuring and pitting. 
The microcrack deepen perpendicularly in the direction of the forces of tangential cutting 
and along fibrils of collagen. Vertical form in the subchondral bone cartilage. Clusters of 
chondrocytes appear around these clefts and at the surface. 
Phase 3: erosion 
 Fissures cause fragements of cartilage to detach and “fall” into the articular cavity 
osteocartilaginous loose bodies and uncovering the subchondral bone. Subchondral 
microcysts develop These fragement cause the mild synovial inflammation of OA. 
 The resulting inflammation often is more focal than inflammation that occurs 
during rheumatoid synovitis.  Histologically, OA synovitis is characterized by mild, 
nonspecific lymphoplasmocytic and histiocytic infiltration. 
 There is sclerosis of the subchrondral bone, due to the apposition of small strips of 
new bone.  Osteophytes form around the zone, their surface covered with fibrilar 
cartilage.  Subchondrol sclerosis increases with disease progression.  Specific changes in 
architecture of he subchondral trabecular bone are due to accelerated bone turnover. 
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AETIOLOGY  
Aetiology 
 The causes of osteoarthritis are varied. 
Endocrine: 
 People with diabetes may be prone to osteoarthritis.  Other endocrine problems 
also may promote development, including acromegaly, hypothyroidism, 
hyperparathyroidism, and obesity. 
Post traumatic: 
 Traumatic causes can be further divided into macrotrauma or microtrauma.  An 
example of macrotrauma is an injury to the joint such as bone break causing he bones to 
line up improperly (mal alignment), lose stability, or damage cartilage.  Microtrauma 
may occur over time (chronically).  An example of this would be repetitive movements or 
the overuse noted in several occupations. 
Inflammatory joint disease: 
 This category would include infected joints, chronic gouty arthritis, and 
rheumatoid disease. 
Metabolic: 
 Diseases causing errors of metabolism may cause osteoarthritis.  Examples 
include padget disease and Wilson disease. 
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Congenital or developmental: 
 Abnormal anatomy such as unequal leg length may be a cause of osteoarthritis. 
Genetic: 
 A genetic defect my promote breakdown of the protective architecture of 
cartilage.  Examples include collagen disturbances such as Ehlers-Danlos syndrome. 
Neuropathic: 
 Diseases such as diabetes can cause nerve problems.  The loss of sensation may 
affect how the body knows the position and condition of the joints or limbs.  In other 
words, the body can’t tell when it is injured. 
Other: 
 Nutritional problems may cause osteoarthritis.  Other disease such as hemophilia 
and sickle cell anaemia are further examples. 
Secondary Causes of Osteoarthritis 
¾ Calcium deposition. 
¾ Congenital or development 
¾ Endocrine 
¾ Genetic defect 
¾ Infectious 
¾ Metabolic Neuropathic 
¾ Post – traumatic 
¾ Rheumatologic diseases (Other than primary osteoarthritis) 
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Classification of Osteoarthritis 
 Osteoarthritis is a common cartilage disease and a major cause of pain and 
disability in older adults.  Primary osteoarthritis results from changes caused by specific 
inflammatory or metabolic conditions, while secondary osteoarthritis is caused by other 
conditions that damage cartilage. 
Primary Osteoarthritis Secondary Osteoarthritis 
Usually limited to one or a small number of 
joints 
May be limited to a small number of joints 
if injury – related, or may be in joints 
throughout body, if disease related 
No specific inflammatory or metabolic 
condition known to be associated with 
arthritis is present 
Conditions that cause damage to cartilage 
are present, such as; 
¾ Inheritied diseases of iron, calcium 
or coper storage such as 
hemochromatosis, 
hyperparathyroidism, or Wilson’s 
diseases. 
¾ Neurologi disorders that result in the 
loss of nerve function. 
¾ Congenital diseases that cause an 
imbalance in the joints 
No history of specific injury or trauma History of injury to joints, such as fractures 
and tears, or history of trauma to joints, 
such as repetitive heavy lifting or kneeling 
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Signs and symptoms 
 The most common signs and symptoms of osteoarthritis are  
¾ Joint soreness after periods of overuse or inactivity. 
¾ Stiffness after period of rest that goes away quickly when activity resumes. 
¾ Morning stiffness, which usually lasts no more than 30 minutes. 
¾ Pin caused  by the weakening of muscles surrounding the joint due to inactivity. 
¾ Joint pain is usually less in the morning and worse in the evening after a day’s 
activity 
¾ Deterioration of coordination, posture and walking due to pain and stiffness. 
Diagnosis 
 There is no single sign, symptom, or test result that allows a definitive diagnosis 
of osteoarthritis.  Instead, the diagnosis is based on a consideration of several factors, 
including the presence of the characteristic signs and symptoms of osteoarthritis and the 
results of laboratory tests and x-rays. 
Diagnostic criteria 
 Formal criteria and helpful for diagnosing osteoarthritis in knee joints.  The 
criteria for osteoarthritis of the knee include the presence of knee pain plus at least three 
of the following characteristics: 
¾ Age greater than 50 years 
¾ Morning stiffness lasting less than 30 minutes 
¾ Crackling or grating sensation (crepitus) 
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¾ Bony tenderness of the knee 
¾ Bony enlargement of the knee 
¾ No detectable warmth of the joint to the touch. 
Complications list for Osteoarthritis: 
 The list of complications that have been mentioned in various sources for 
Osteoarthritis includes; 
Life style effects include 
¾ Depression 
¾ Anxiety 
¾ Feelings of helplessness 
¾ Limits on daily activities 
¾ Job limitations 
¾ Loss of everyday family joys and responsibilities 
¾ Rapid, complete breakdown of cartilage resulting in loose tissue 
¾ Material in the joint (Chrondrolysis). 
¾ Bone death (Osteonecrosis). 
¾ Stress fractures (hairline crack in the bone that develops). 
¾ Gradually in response to repeated injury or stress 
¾ Bleeding inside the joint 
¾ Infection in the joint 
¾ Rupture of the tendons and ligaments in the joint. 
¾ Pinched nerve (in osteoarthritis of the spine). 
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ANATOMY OF THE KNEE JOINTS 
 This hinge joint is formed by the condyles of the femus, the condyles of the tibia 
and the posterior surface of the patella.  The anterior part of the capsule consists of the 
tendon of the quardriceps femoris muscles which also supports the patella. 
 Intracapsular structures include two cruciace ligments which cross each other, 
extending from the intercondylar notch of the femus to the intercondylar eminence of the 
tibia.  They help to stabilize the joint. 
 Semilunar cartilages of menisci are incomplete discs of white fibro cartilage lying 
on top of the articular condyles of the tibia.  They are wedge –shaped, being thicker at 
their outer edges.  They help to stablize the joint by preventing lateral displacement of the 
bones. 
 Bursae and pads of fat are numerous.  They prevent friction between a bone and a 
ligament or tendon and between the skin and the patella.  Synovial membrane covers the 
circiate ligaments and the pads of fat. 
 The menisci are not covered with synovial membrane because they are weight – 
bearing.  The most important strengthening ligaments are the medial and lateral collateral 
ligaments. 
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ARTICULAR CARTILAGE 
 The ends of the bones in a snovial joint are covered with a layer of articular 
cartilage.  This is an avascular tissue that consists of cartilage cells 9chondrocytes) 
embedded in a thick matrix of proteoglycans, water, type II collagen and smaller amounts 
of other proteins. 
 Although there is no cell division in normal cartilage, chondrocytes are 
metabolically active cells that are responsible for synthesis and turnover of cartiage 
matrix throughout life.  The matrix consists of meshwork of type II collagen fibrils that 
run through a hydrated ‘gel’ of proteoglycan molecules, the most important of which is 
aggrecan. 
 Aggrecan consists of a core protein, to which several glycosaminoglycan (GAG) 
side – chains are attached.  GAGs consist of long chains of disaccharide repeats, in which 
the disaccharide consists of one ordinary sugar linked to an amino sugar. 
 The most important GAGs in aggrecan are chondroit in sulphate (glucoronic acid 
and sulphated N-acetygalactosamine) and keratan sulphate (galactose and sulphated N-
acetlglucosamine).  Cartilage also contains hyaluronan, a long GAG consisting of 
multiple glucoronic acid and N- acetylgalactosamine disaccharide repeats. 
 Hyaluronan binds several aggrecan molecules by interacting with a domain at the 
N-terminus of the core protein along with a small glycoprotein called link protein that 
acts to stabilize the complex..  Large complexes of a aggrecan and hyaluronan can form 
in catilage with a total molecular weight in excess of 100 million. 
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INTEGRITY OF THE KNEE JOINT 
1. Lateral motion of the knee joint in extension is controlled by capsule, collateral 
ligaments and cruciate ligaments, in flexion, by the same structures minus the 
fibular collateral ligament. 
2. Rotatory motion of the knee joint in extension is controlled by the capsule, 
collateral ligaments and cruclate ligaments, in flexion, by the same structures 
minus the fibular collateral ligament. 
3. Forward gliding of the tibia on the femur is controlled by the anterior curciate 
ligament and the quadriceps. 
4. Backward guiding of the tibia on the femur is controlled by the posterior cruciate 
ligament and the posterior capsule. 
5. Lateral gliding of the tibia on the femur is controlled by the tibia, intercondylar 
spine and the femoral condyles with the aid of all the ligaments. 
6. Hyperextension is controlled by both collateral ligaments, both cruciate ligaments, 
both menisci, the posterior aspect of the articular capsule, the oblique popliteal 
ligament and the architecture of the femoral condyles. 
7. Hyperflexion is controlled by both cruciate ligaments, both menisci, the femoral 
attachment of the posteior aspect of the capsule, the femoral attachement of both 
heads of gastrocnemius muscle, and the bony structure of the condyles of the 
femur and the tibia. 
8. The menisci cushion hyperextension and hyperflexion.  The tibial collateral 
ligaments is closely related to the medial meniscus but there is no strong fibrous 
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tissue attachment between them.   The tibial collateral ligament glides forward 
and backwards in extension and flexion. 
 Aggrecan has a strong negative charge because of the sulphate any hydroxyl 
groups in the GAG residues: as a consequence, it binds large numbers of water molecules 
to assume a shape that occupies the maximum possible volume available  The expansive 
force of the charged and hydrated aggrecan, combined with the restrictive force of the 
collagen meshwork, gives articular cartilage excellent shock – absorbing properties. 
 With ageing, the amount of chondroitin sulphate in cartilage decreases, whereas 
that of keratan sulphate increases.  The end result is a reduction in water content and 
impairment of cartilage’s shock absorbing properties.  Age – related charges in cartilage 
differ from those found in osteoarthritis, where there is abnormal chondrocyte division, 
loss of proteoglycan from matrix and an increase in water content. 
 Cartilage matrix is constantly being turned over, and in health a perfect balance is 
maintained between synthsis and degradation of matrix components.  Matrix degradation 
is throught to be mediated by proteolytic enzymes such as aggrecanse and matrix 
metalloproteinases that degrae the core protein of aggrecan and other matrix proteins.  
Other enzymes termed glycosidases degrade the GAG side – chains. 
 The importance of this system is emphasized by the occurrence of a group of 
diseases, termed mucopolysaccharidoses, in which genetic mutation in glycosidases 
occur, resulting in excessive accumulation of GAGs in various tissues. 
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 The mechanisms by which proteoglycan turnover is regulated in normal cartilage 
are poorly understood, but pro – inflammatory cytokines such as interleukin – 1 (IL –1) 
and tumour necrosis factor (TNF) which are involved in joint inflammation are known to 
upregulate production of aggrecanase, metalloproteinases and other enzymes that cause 
matrix degradation, thereby promoting cartilage damage. 
 This is offset by upregulation of inhibitors of proteinases in cartilage, called tissue 
inhibitors of metalloproteinases (TIMP), which oppose the effects of degrading enzymes 
and protect against matrix degradation. 
Zones of articular cartilage: 
1.  Superficial Layer (tangential Zone) 
 Makes up 10% of cartilage 
 Consists of 2 sub – zones  
 i.  Fibrilar Sheet / Lamina Splendens is the more superficial layer. 
        Clear film consisting of a sheet of small fibrils with little polysaccharide and  
   no cells. 
 ii.  Cellular layer with flattened chondrocytes. 
  Flat chjondrocytes and collagen fibers are arranged tangentially to the articular 
surface. 
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 Thinnest layer, with highest content of collagen and the lowest concentration of 
proteoglycans. 
 Collagen (type IX) is arranged at right angles to adjacent bundles and parallel to 
the articular  surface. 
 Subsequently has greatest ability to resist shear stresses and serves as a gliding 
surface for joint. 
 May also function to limit passage of large molecules between synovial fluid and 
cartilage. 
 Superficial zone is the first to show changes of osteoarthritis. 
2.  Transitional Layer. 
- This zone is involves transition between the shearing forces of surface 
layer to compression forces in the cartilage layers. 
- Composed almost entirely of proteoglycans 
- Spherical chondrocytes. 
- Less strongly bound 
3.  Deep radial layer: 
- Largest part of the articular cartilage 
- It distributes loads and resists compression 
- Collagen fibers and chondrocytes are perpendicular to the subchondral 
plate 
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4.  Calcified Cartilage Layer: 
- Contains the tidemark layer 
- Tidemark is pasophilic line which straddles the bound between calcified 
and uncalcified cartilage. 
- Separes hyaline cartilae from subchlodral bone 
- Type X collagenm is present mainly in the calcified cartilage layer and in 
hypertrophic zone of the growth plate. 
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PROTOCOL 
1. BACKGROUND  
Osteoarthritis is a non - inflammatory disorder of movable joints characterized by 
detorioration of articular cartilage and formation of new bone at the joint surfaces and 
margins. This disorder is also known as degenerative joint disease. Osteoarthritis at Knee 
joints is the leading cause of chronic disability in developed countries. The distribution of 
osteoarthritis in men & women is similar. Ages between 40-65Yrs commonly affected. In 
this age group, the prevalence is 68%. 
In Siddha system, Azhal keel vaayu is the equivalent to osteoarthritis. 
According to Siddha literature, Azal keel vaayu is one of the types of keel vaayu 
diseases. Keel vaayu disease is one among the 80 Vaatha diseases that is called 
Santhuvaatham. It is also called as Mootuvali and Santhusoolai. 
About the disease 
 “hqk<k!gQz<uiB!ke<eix<!gQz<Lm<MuQr<gqs<!
! sqk<kI!osb<lVk<Kus<!sQIhmik!ke<jlkigqk<!
! kk<kie!gib<s<sz<!g{<M!sizOu!kjekie!kf<Ok!
! olk<kX!sqgqs<js!ke<ekz<!ole<Olz<!fQg<Glh<hi”!
.!shihkq!jgObM!
!
!
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! -K,!utqg<Gx<xl<!ke<eqjzbqz<!lqGf<Kt<tOhiK!npz<!Gx<xk<jkk<!K~{<mg<!
%cb!d{U,!osb<jg!Lkzqbux<xiz<!hqxg<Gl<!Ofibil</!!-f<Ofibqz<,!Lm<cgtqz<!
d{<miGl<!uQg<gl<!fiTg<Gfit<!ohVk<Kg<!ogi{<Om!uf<K,!lqGf<k!kQg<Gx<xk<kiz<!
gQz<gtqeqjmObBt<t! hjs! ux{<M! hjsbx<Xg<! gQz<! njsBl<! Ohiokz<zil<!
fm<jmBjmkZl<! #gZg<#! #gZg<#! oge<x! YI! yzq! d{<miuKlib<! -Vg<Gl</!!
sqzOujtgtqz<!gQZg<Gg<!gQz<!%c!ym<cg<ogi{<M!yV!gpqOhiz!lmg<g!LcbilOz!
fqe<X!uqMuKl<!d{<M/!!-f<Ofib<g<G!sqXSvLl<!uVl</!
! It is characterized by swelling of joints associated with severe pain and pyrexia.  
Since it is not quickly responding to medicine the prolongs medical care is said to be 
essential.  As piththa increases, kaba (mucuous) in the joint decrease and hence dryness 
occur.  So, during flexion of the joint crepitation is produced.!
In Siddha text, Korakkar Santhraregai there is a preparation named Mirutharsingi 
Chunnam which is indicated for vaatham 80. In Ugimunivaithyakaaviam text, there is a 
external drug called poochu ennai which is indicated for muzhangal piddipu. 
So, I would like to estimate their efficacy for the treatment of Azhal keel vaayu. 
2. AIMS 
(a) Primary aim  
To estimate the efficacy of Mirutharsingi Chunnan and Poochu ennai in the 
treatment of Azhal keel vaayu 
(b) Secondary aim 
To find out the side - effects of the drugs, if any. 
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3.  POPULATION & SAMPLE 
The population consists of all patients with Azhal keel vaayu satisfying the 
inclusion and exclusion criteria mentioned below.  The sample consists of patients 
attending the IPD/OPD of the Ayothidoss Pandithar Hospital of the National Institute of 
Siddha, Chennai – 47. 
4.  SAMPLE SIZE 
The trial size will be 50 patients  
5. INCLUSION CRITERIA 
1. Aged between 40 and 65yrs. 
2. Willing to give blood specimen & willing to take X-ray for the investigation when 
required. 
3. Willing to be in – patient for 48 days, or willing to attend OPD once in 8 days for 
48 days. 
6.  EXCLUSION CRITERIA 
1. Hypertension   
2. Stomach carcinoma  
3. Peptic Ulcers 
4. Hypercholestremia 
5. Cardiac ailments  
6. Severe neurological disorders. 
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7. WITHDRAWAL CRITERIA 
1. Any drastic changes occurring in haematological parameters & in urine analysis. 
2. Development of any gastro-intestinal disturbances. 
1. Occurrence of any other serious illness.  
8. TRIAL DRUG & DURATION 
Purgation:  Siththathi ennai   - 10 ml with sombukudineer (at early morning) 
– First day on admission 
Mirutharsingi chunnam -  65 mg with Ghee – twice a day,  after food 
Poochu ennai - q.s. - External application 
Trial treatment period - 48days. 
9. TESTS & ASSESSMENTS  
(a) Clinical assessment 
 Pain, swelling, warm, redness, tenderness, morning stiffness,   crepitations, 
periarticular muscle atrophy, movements of the joints, measurements of the joints in both 
knee joints. 
(b) Investigations 
1. Blood test: TC, DC, ESR, Hb, Blood urea, Serum cholesterol, Blood sugar. 
2. X-ray findings. 
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10. CONDUCT 
Azhal Keel Vaayu patients satisfying the inclusion & exclusion criteria will be 
admitted to the trial. Informed consent will be obtained from the patients. 
A day before starting trial treatment, cleansing of Vaatha Kuttram by purgation 
will be carried out.   X-ray will be taken before treatment and at the end of the treatment. 
Lab investigations will be carried out before treatment, on 24th day and at the end of the 
treatment. 
For IP patients, the trial drug   will be administered by the doctor. For Op patients, 
the trial drugs will be issued for 8 days.  They will be asked to come to Op with 
unconsumed medicines and return them. On the 8th day, the trial drug will be given to the 
patient for another 8 days. At each clinical visit, clinical assessment will be done.  
11. FORMS 
Form I -  Selection proforma -  Used before admission of the patients to the  
      trial. 
Form II - Assessment proforma   - Used once in 8 days during treatment. 
12. ANALYSIS 
Changes in the proportion of patients before and after treatment for signs and 
symptoms will be analysed using paired X2 - test. 
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RESULTS AND OBSERVATION 
Table 1 Gender distribution  
Gender Cases 
No. Percentage 
Male 28 46.7 
Female 32 53.3 
Total 60 100.0 
Observation: 
 Among the selected 60 patients, the prevalence of the disease was found to be 
higher in females i.e. 53.3%. 
Table 2 Age distribution  
Age 
(years) 
Cases 
No. Percentage 
31 – 40 2 3.3 
41 – 50 16 26.7 
51- 60 28 46.7 
61 – 70 14 23.3 
Total 60 100.0 
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Observation: 
 The prevelance of the disease was found to be higher in the age group 51-60 
years. 
Table :3 Kaalam (Life span) 
Kaalam Cases 
No. Percentage 
Vaathakaalam (up to 33 yrs) 0.0 0.0 
Piththaakaalam (34-66 yrs) 54 90.0 
Kaba Kaalam (above 67 yrs) 6 10.0 
Total 60 100.0 
Observation: 
Out of 60 cases, 90% of the cases were found to be in Piththakaalam i.e. between 
33 –66 years. 
4.  Paruvakaalam 
 Among 60 patients, 42 (70%) cases were admitted to the trial in Koothirkaalam 
and the remaining 18 (30%) cases were admitted in Munpanikaalam 
 No case was admitted in Kaarkaalam, Pinpanikaalam Elavenil Kaalam, 
Muthuvenil Kaalam. 
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5. Diet 
Diet Cases 
No. Percentage 
Vegetarian 6 10.0 
Non-Vegetarian 54 90.0 
Total 60 100.0 
Observation: 
Out of 60 cases 90% of cases were non-vegetarian 10% of cases vegetarian. 
6.  Thinai: 
 Most of the cases (90%) were reported from Neithal thinai. 
 The remaining 10% of cases reported from Marutha Nilam. 
6.  Socio economic status: 
Socia Economic Status Cases 
No. Percentage 
Poor 18 30.0 
Middle class 40 66.7 
Rich 2 3.3 
Total 60 100.0 
Observation: 
 The incidence of the disease was found to be higher in middle class (66.66%). 
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7.  Disturbances in Vaatham: 
 Out of 60 cases observed viyaanan and samanan were affected in almost all the 
cases while abanan affected in 5 cases. 
8.  Disturbances in Piththam: 
 Out of 60 cases, Saathagam was affected in almost all cases. 
9.Disturbances in Kabam: 
 Only Santhigam was affected in all the 60 cases. 
10.  Envagai Thervugal (Siddha Diagnostic Parameters) 
 Almost all cases affected were observed altered naadi and sparism, malam in all 
5% and vizhi in 8.3%. 
11. Naadi 
Naadi Cases 
No. Percentage 
Vaatha piththam 44 73.3 
Vaathakabam 5 8.3 
Piththavaatham 8 13.3 
Piththakabam 2 3.3 
Kabavaatham 1 1.7 
Kabapiththam 0 0.0 
Total 60 100.0 
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12.  Neikuri 
Spreading Pattern Cases 
No. Percentage 
Aravenaneendathu 11 18.3 
Aazhipolparaviathu 0 0.0 
Muththupol Ninrathu 49 81.7 
Total 60 100.0 
13. Udal Thathukkal: 
 Enbu was affected in all 60 cases (100%) . 
 Saaram also affected in all 60 cases (100%) 
14.  Disturbances in Kanmenthiriyam: 
 Kaal was affected in all 60 cases (100%) 
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15.  Duration of Illness: 
 Duration of Illness 
(month) 
Cases 
No. Percentage 
Up to 6 months 37 61.7 
7 – 12  months 20 33.3 
13 –18 months 3 5.0 
19 – 24 months 0 0.0 
25 – 30 months 0 0.0 
Above 30 months 0 0.0 
Total 60 100.0 
16.  Involvement of Knee Joints 
Knee Joints Cases 
No. Percentage 
Both Knee Joints 50 83.3 
Right Knee joint only 8 13.3 
Left Knee Joint only 2 3.3 
Total 60 100.0 
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17.  Clinical Features 
Clinical Feature Cases 
No. Percentage 
Pain 60 100.0 
Swelling 60 100.0 
Warmth 60 100.0 
Tenderness 60 100.0 
Morning stiffness 60 100.0 
Crepitation 60 100.0 
Periarticular muscle atrophy 0 0.0 
Instability 7 11.7 
Deformity 14 23.3 
Restricted movements 60 100.0 
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18.  Precipitating Factors: 
Factors Cases 
No. Percentage 
Obesity 8 13.33 
Menopause 30 50.0 
Increased house maintenance 17 28.33 
Occupational related 13 0.0 
Diabetes Mellitus 10 16.7 
History of Trauma 1 1.7 
H/o. Injury 1 1.7 
H/o. Fractures 1 1.7 
H/o. Chikungunya 1 1.7 
19.  Occupational: 
Occupation Cases 
No. Percentage 
Clarical worker 15 25.0 
Teacher 5 8.3 
Watchman 20 33.3 
Tailor 10 16.7 
Farmer 10 16.7 
Total 60 100.0 
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20.  Results 
Results Cases 
No. Percentage 
Good Improvement 50 83.3 
Moderate Improvement 10 16.6 
Mild Improvement 0 0.0 
No Improvement 0 0.0 
 
83.3
16.7
Good improvement Moderate improvement
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Table No.  Results of Statistical Analysis Objective parameters observed Before 
and After Treatment of 60(n)  patients of Azhal keel vaayu 
National Institute of Siddha, Chennai – 600 047, During 2007-08 
 
 
Parameter 
Mean Paired t-test Probability 
(P) Value 
Statistical Significance of 
the Difference Before Rx After Rx Difference
1a. 
Joint 
circumberernce 
(cm) 
      
 
Right knee 
joint(cm) 
N=58 
44.2 43.3 0.9   t  = 23.238 P< 0.05 Significant 
1b 
Joint 
circumberernce 
(cm) 
      
 
Left knee 
joint(cm) 
N=52 
45.6 44.6 1.0 t  = 33.669 P< 0.05 Significant 
2. 
Total RBC’s 
Million 
cells/cumm 
3.96 4.05 0.09 t  = 2.827 P< 0.05 Significant 
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DISCUSSION 
Azhal keel vaayu is one among the ten types keel vaayu as mentioned in siddha 
maruthuvam text the symptoms of azhal keel vaayu more or less correlates with 
osteoarthirtis in modern medicine. 
For this dissertation study 60 patients were selected and 20 patients were admitted 
in National Institute of Siddha , Sirappumaruthuvam in-patient ward and 40 patients were 
treated in out patient department with the trial drug. 
These drugs which possess anti-Vaatha property as mentioned in siddha literature   
were selected and the trial drug was prepared as per the text. 
The biochemical, pharmacological and toxicological study of the trial drug were 
tested in the laboratories of the results were documented. 
Based on various criterias, the datas were colleted and tabulated the criterias were 
the gender predominance, incidence of the disease with respect to the age, kaalam (life 
span), seasonal variation, clinical manifestation, relation to menstrual cycle, diet and the 
assessment of the improvement in the prognosis of the disease with the trial drug. 
The incidence of the disease was found to be more predominant in females 
(53.3%) and majority of the cases were reported in the age group above 40 years.  
Post menopause  is one of the criteria which increases the incidence of the disease 
(50%) in females 
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As mentioned in siddha literature the diseases was common in pithakaalam 
(between 34-66 years. 
The changes were also noted in udal Thathukkal, Envagai Thervugal, 
Kanmeanthirium, Udal Vanmai, Mukkuttrams. This also aids in the diagnosis of the 
deranged Kuttrams. 
The major clinical symptoms were reported to be pain, swelling in the affected 
joint,  difficulty in movements of the knee jts. 
Laboratory investigations of Blood, Urine, Stools were done for all 60 cases . 
Out of 60 cases,  8 cases found to have diebeties mellitus. These patients 
confirmed their oral anti diabetic drugs which they were taking previously along with the 
trial drug these patients were given anti-diabetic drug along with the trial drug. The blood 
sugar levels were monitored and kept control during the treatment. 
There was much remarkable change in the Total Count, ESR, Total Red Blood 
Cells, Haemoglobin. ESR has been decreased, whereas  Total Count, Total Red Blood 
Cells, Haemoglobin increased. 
Urea, Serum Creatine levels not much remarkable changes. 
The radiographic studies of the cases showed narrowed joint space, presence of 
osteophytes, Soft tissue swelling. The trial drugs showed improvement in prognosis of 
the disease clinically rather in radiographic changes. 
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SUMMARY 
The clinical study on Azhal Keel Vaayu with reference to its aetiology, 
pathogenesis, investigations, clinical features, diagnosis and treatment were conducted at 
the Sirappumaruthuvam Department, National Institute of Siddha, Chennai – 47 
60 cases with the signs and symptoms of Azal Keel Vaayu were selected and a 
thorough observation was made.  
The majority of patients were female. 
The drugs administered in the clinical study were used only after careful purification 
process 
During the study period, there were no drug reactions like tiredness, nausea, vomiting, 
abdominal pain, gastric discomfort, weakness reported  
Among 60 the patients treated 90% showed good results. 10% showed moderate results. 
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CONCLUSION 
Treatment was given for the Azhal Keel Vaayu on the basis of “Mukkutra 
Theory”.  The deranged Kuttrams were corrected by the medicine given. 
Mirudharsingi chunnam and poochuennai as on internal & external respectively. 
The above medicine were selected from the Siddha literatures korakkar 
santhraregai and Yugimunivaidhya kaaviyam respectively.  Almost all the cases with 
above medicines were shown remarkable improvement. 
Clinically, no adverse effects were reported during the course of treatment and the 
drug evaluation was done with modern parameters. 
Reversible pharmacological effects found by modern parameters for this drug. 
A length it is concluded that in the treatment of Azhal Keel Vaayu with 
Poochuennai were found to be very safe and also economical. 
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PROPERTIES OF TRIAL MEDICINES 
lqVkiIsqr<gqs<!S{<{l<!
! d{<mokiV!gx<hlqjk!Bjvh<Oh!eqr<G!
! ! d{<jlBme<!LkiIsqr<OgiI!hzOl!ogi{<M!
! u{<jlBxk<!kqVfQx<Xs<!siX!ke<eiz<!
! ! uZuigk<!kqiqfiTl<!Nm<ch<!hqe<eI!
! h{<MOhiz<!um<Ms<osb<K!vuqB!zIk<kqh<!
! ! hir<gigg<!Gg<Gmlil<!HmLl<!Jf<K!
! os{<MOhiz<!-m<omMg<gs<!S{<{!liGl<!
! ! sqk<kIgTl<!g{<Muqm<miz<!ogi{<Om!OhiuiI!
!
! ogi{<muIgt<!Ohigilz<!-Vh<h!kx<G!
! ! Yl<.nl<.dl<.zl<!ole!oshqg<gg<!
! g{<Mdjes<!sqk<kIgTl<!uvr<gt<!=uiI!
! ! gisqeqbqz<!-l<lVf<jkg<!gijz!lijz!
! d{<cMuib<!l{<mzOl!Nuqe<!ofb<bqz<!
! ! djzbiK!gx<X~{<Ohiz<!kqOvgr<!gif<kq!
! s{<meqz<jz!uikol{<!hKUl<!OhiGl<!
! ! siIf<kqmOu!HtqOhigl<!ngx<xqg<!giOv!
!
! giIk<kqmOu!G{<mzqkie<!uisqkiEl<!
! ! gtr<glx<X!uZuigqs<!Osikq!kr<Gl<!
! H,Ik<kqBx<Xh<!H,v{Ol!zLkl<!ohir<gqh<!
! ! Hgp<ohiqb!Riesqk<ke<!fQOb!biuib<!
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! gQik<kqBx<Xh<!hkqoe{<OhI!ogi{<m!gx<hl<!
! ! %xqOee<!uikqgOt!uqtl<hg<!Og{<lqe<!
! OfIk<kqBme<!Sk<kqk<k!out<tq!osl<hqz<!
! ! =f<kqmOu!sqr<gqs<!S{<{l<!lix<oxm<!miOl!
!
lqVkiI!sqr<gq!!.2!hzl<!
! kqVfQx<Xh<!hs<sqjz!siX! .!Okjubie!ntU!
! lqVkii!sqr<gqjb!kqVfQx<Xh<!hs<sqjz!siX!uqm<M!4!fim<gt<!njvk<K!
hm<MOhiz<!osb<K!gib!juk<K!S,iqb!ouh<hk<kqz<!dzIk<kq!OgipqHml<!6!Ljx!
Ohim!S{<{liGl</!
!
! ! ntU!! ! ! .!niqsqobjm!)76lqz<zq!gqvil<*!
! ! nEhiel<! ! ! .!hSofb<!)gijz,!lijz!-v{<M!Oujt*!
! ! lVf<K{<[l<!giz!ntU! .!2!l{<mzl<!)59!fim<gt<*!
kQVl<Ofib<!! ! ! .!uikl<!91!! !
hk<kqbl<! ! ! .!Htq,!Ohigl<!
!
!
!
!
!
!
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lqVkiIsqr<gq!
Galena Sulphie of Lead, Lead ore 
  OuXohbIgt<!! ! .!!sqr<gq,!LkiIsqr<gq,!sqr<G!!
  osb<jg! ! ! .!!KuIh<hq!!
! ! ! ! ! ! !!GtqIs<sqB{<mig<gq!
! ! ! ! ! ! !!HPg<ogiz<zq!
ohiKG{l<!
! #lqVkiv!sqr<ogeOu!olz<zUjvk<!kiZ!
! LVuiI!Hjmgvh<hi!OeiM!.!oliVuqkOli!
! sizs<!sqvr<GG{<[f<!kh<hil!zixquqMl<!
! Ouozik<k!g{<lbqOz!uqt</#!
ohiVt<!
! lqVkiVsqr<gqbqeiz<!dml<ohr<Gl<!hvUgqe<x!hjm,!gvh<hie,<!gqvf<kqg<!%m<ml<!
lgiuqv{l<!-ju!fQr<Gl</!
lqVkiIsqr<gqs<Sk<kq!
! osb<BlkiI!sqr<gqs<Sk<kq!osiz<zg<OgT!
! ! kqxliL!kivsqr<gqg<!gm<cuir<gq!
! Jblqzi!out<tim<Mg<!Ogilbk<kqz<!
! ! ne<HmOe!kie<Ohim<M!Ougjuk<Kh<!
! jhbOu!Nxuqm<M!njkobMk<Kh<!
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! ! hg<Gulib<s<!S{<{s<osf<!K~vR<osb<b!
! olb<big!big<OgiH!osie<Oe<hiV!
! ! OlkqeqObiIg<!gqKfz<z!liIg<gf<kiOe!
! lqVkiI!sqr<gqjb!uir<gq!yV!sim<cbqz<!out<tim<M!OgiOlbl<!hqck<K!nkqz<!
lqVkiI!sqr<gqjbh<!Ohim<Ms<!sm<cjb!nMh<Ohx<xq!yV!fipqjgujv!ogikqg<g!
juk<kokMk<Kg<!gibjug<gs<!Sk<kqbiGl</!
hSuqe<!ofb<!
Cow’s Ghee 
 kig!LpjzSm<gR<!sIk<kqhqk<kl<!uiBhqv!
! Olgl<!ubqx<oxiqU!uqg<gzpz<!.!ligisr<!
! Ge<ll<!uxm<sq!Gmx<Hvm<m!z <^kqSm<gR<!
! osie<&zl<!Ohig<Gfqjvk<!Kh<H!
! hSuqeK! ofb<bieK! kigl<,! dpjzh<! hq{q,! nkqSm<gOvigl< ,! uif<kq,!
hqk<kikqg<gl< ,!uikuq]ll< ,!uqv{h<hqvOlgl< ,!ubqx<xqoziqU,!hqk<kuqg<gz,<!-Vlz, <!
ubqx<Xuzq,! sqjeh<H,! Gmz<! oftqkz< ,! wZl<HVg<gq! hz! &zOvigl<! Ngqb!
-jugjt!fQg<Gl</!
kqVfQx<Xh<hs<js!
Ocimum basilicum,. Linn 
 Family  : Lamiaceae 
 English Name : Sweet Basil 
 Part Used : Whole Plant 
 Sju! ! ;!giIh<H!)uqXuqXh<H*,!ke<jl!;!ouh<hl<,!!hqiqU!;!-eqh<H!
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osb<jg!!
! ! OuI!
! uqbIjuB{<mig<gq!!- Diaphoretic 
! ngm<Muib<ugx<xq  - Carminative!! !
! ouh<hL{<mig<gq! .!Stimulant 
uqjk!
uPuPh<H! ! - Mucilaginous 
! dt<tpzix<xq!  - Damulcent!
! sqXfQIh<ohVg<gq! .!Diuretic 
  siX!
! HPg<ogiz<zq!! .!Anthelmintic 
ohiKG{l<!
 kqVfQx<Xh<hs<js!sqOz]<lsIk<kq!ke<je!
! uqiqfQx<jxh<!Ohizig<G!olb<Ob!.!ohiqb!
! Svk<kqvk<k!uif<kq!SvlVsq!fqz<zi!
! Uvk<kqvs<s!jmg<Og!Bjv!
- G{himl<!&zqjg!uGh<H!
ohiVt<;!
! -keiz<!Jbl<,!uif<kq!Lkzqbux<jxBl<!Svk<kiz<!hqxg<gqe<x!GVkq,!uif<kq!
Lkzqbux<jxBl<!Ohig<Gl</!!!
 s&zl<!uikk<jk!fQg<g%cbK!
 -keiz<!ubqx<jxs<!OsIf<k!Ofib<gt<!kQVl<!
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 Juvocimene I an juvocimene II isolated from oil and their structures determined 
and confirmed by synthesis (J.Chem. Ecol. 1984, 10, 1453: Chem. Abstr. 1985, 102, 
75696 a): leaves afforded thymol, xanthomicrol and butyl caffeate 9planta med 1988, 54, 
190): methyleugenl 933.95) and eugenol (23.1%) determined as major components in 
supercritical carbon dioxide. 
 New sesquiterpene hyderocarbon – 1 – epibicyclosesquiphellandrene – isolated 
from oil (phytochemistry 1974, 13, 1183); methl chavicol (90%) and linalool present in 
essential oil obtained from green leaves (Tap. Chi Hoa Hoc 1977, 15, 29; Chem. Abstr. 
1978, 88, 158268 v). 
!
!
!
!
!
!
!
!
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H,s<Sob{<o{b<!
! g{<Ciqe<eLmg<ogik<kie<!giqhie<sivj{Gh<jhOleq!
! ogi{<OmOuzqh<hVk<kqKvib<!%m<cg<gicobiVfipq!
! ne<Ox!siXfieipq!bil{k<og{<o{b<fieipq!
! obie<xib<g<%m<ogib<s<squck<!KmOekmuUmz<!lQOk!
! ! dmzlkeqx<xi{<mu!obiMr<GkqVGuiklK!
! gmz<Ohiz<kqjvBr<gpz<uikl<!glPolipqBl<!uiklK!
! nmzil<g{<muikLm!er<g{<Lpf<kit<hqch<HgTl<!
! kqmlib<h<OhiGoleLequI!kqxf<kiIB,gqohVF~Oz!
!
! Lmg<gk<kie<,!!
giqsijz,!!
Gh<jhOleq,!!
Ouzqh<hVk<kq,   Ngqbux<xqe<!siX!hqpqf<K!fie<G!fipq  )6/3!zq*!!
sivj{,!!
Kvi!!
!
gic!! ! ! .! yV!fipq!)2/3!zq*!
Nl{g<og{<{b<!! .! fie<Gfipq!)6/3!zq*!
OsIk<K!gzf<K!ye<xigg<!gib<s<sq!uck<K!dmzqz<!kmuq!uv!Lpf<kit<!
hqch<H!Ngqbju!kQVl</!
!
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Gh<jh!Oleq!
(Acalypha indica) 
Family - Euphorbiaceae 
Sju!.!jgh<H,!giIh<H!ke<jl!!.!ouh<hl<, !hqiqU!.!giIh<H!
osb<jg;!
Kbvmg<gq! !.!Anodyne 
HPg<ogiz<zq! !.!Anthelmintic 
ohVlzl<Ohig<gq! .!Cathartic 
sqXfQIh<ohVg<gq! .!Diuretic 
uif<kqB{<mig<gq! .!Emetic 
Ogijpbgx<xq! !.!Expectrant 
S,kgL{<mig<gq! .!Emmenagogue 
!
ohiKG{l<!
kf<k&!zh<hq{qkQk<!kf<kqMH{<!sIuuqml<!
df<KGe<ll<!uikl<!dkqv&!.!zf<kqeU!
S,zR<S!uisl<!okimIhQ!sr<ghl<Ohil<!
Rizr<ogit<!Oleqbk!eiz<!
!
-ke<!-jzbiz<!utqOfib<,!Gk<kz,!hz<zc!Ofib,<!kQs<Sm<mh<H{<,!hbqI!
ujgbqe<!fR<S,!ubqx<X!uzq,!&zl<,!fjls<sz<,!-jvh<H!&g<GfQI!hib<kz<,!
Ogijp!Ngqbju!fQr<Gl<!
 90
CONSTITUENTS: 
 A cycanogenetic glucoside, Acalyphine, 
 Two alkaloids, viz, avalyphine and triacetonamine 
 An essential oil n – octacosanol, kaempferot, uebrachitol, b-shitosterol 
acetate and tannin (whoe plant); stigmasterol (root) 
 Acalyphamide (as acetae), 
 Aurantia – mide and its acetae, 
 Succinimide calypho lacetate 
 2 – Methyl anthraquinone, 
 Tri –O-methylellagic acid. 
 B- sitosterol and its b –D- glucoside (leaves) 
Lmg<gx<xie<!
Cardiospermum halicacabum. Linn 
 Family  - Sapindaceae 
 osb<jg! .! uiklmg<gq! .! Antivaada 
ohiKG{l<!!
! S,jzh<!hqch<H!osixq!sqvr<G!ue<gvh<hie<!
! gijzk<!okiMuib<Ur<!ge<lzLl<!.!sizg<!
! gmg<gk<ki!OeicuqMr<!gisqeqjb!uqm<M!
! Lmg<gx<xie<!xe<je!olipq!
! -keiz<!gQz<,!sqjeh<H,!gqvf<kq,!gvh<hie< ,!giz<ucjbh<!hx<xqb!utq!
Ngqbju!OhiGl</<!
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giqszir<g{<{q!
Eclipta Prostrata. Linn 
 hbe<hMl<!dXh<H! .! h,{<M!
! Sju!.!jgh<H,!ke<jl!.!ouh<hl,<!hqiqU!.!giIh<H!
osb<jg;!
! hqk<kfQIh<ohVg<gq! .!Chlagogue 
 dvlig<gq! ! .!Tonic 
 dmx<Oxx<xq! ! .!Alterative 
 uif<kqB{<mig<gq! .!Emet 
 fQIlzl<Ohig<gq! .!Purgative 
 uQg<gLVg<gq! ! .!!Deobstruent 
 =vz<Okx<xq! ! .!Hepeto tonic 
ohiKG{l<;!
! #Gvx<gl<lx<!gilijz!Gm<moliM!Osijh!
! Bxx<hi{<M!he<Oei!obipqb!.!fqvx<osie<e!
! olb<bif<!kgjvobik<k!lQtq!!{<[!fx<Hzk<Kg<!
! jgbif<!kgjvobik<kg<!giz<!
! -keiz<!GvZXh<H!Ofib,<!gilijz,!Gm<ml,<!uQg<gl<,!hi{<M,!hz<Ofib<!
Ngqbju!Ohil</!!Dmzqx<!osix<sibZl<!Ntqg<Gt<t!hzLl<!d{<miGl</!
!
!
!
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kvi!!
Fumaria Parviflora. Linn 
 Family   - Fumariacea 
 hbe<hMl<!dXh<H! .!-jz!
! Sju!.!jgh<H,! ke<jl!.!ouh<hl<,! hqiqU!.!giIh<H!
osb<jg;!
! uqbIjuh<ohVg<gq! .! Diaphoretic 
 sqXfQIh<ohVg<gq! .! Diuretic 
 Hpg<ogiz<zq! ! .! Anthelmintic 
 lzlqtg<gq! ! .! Aperient 
!!osb<G{l<!
 H{<gqvf<kq!gm<c!ohiVse<eq!gQmLl<Ohil<!
! g{<Hjgs<sz<!gisr<gkqg<G!ole<hI!.!oh{<gTg<Gh<!
! hiZl<!ohVGLt<Ot!hx<Xkqvs<!sqg<gz<uqMl<!
! wZf<!kviuq!eqjzg<G!
! -K!H{,<!gpjz,!Lh<hq{q!Ofib<gt<,!g{<Hjgs<sz<,!g{<gisl<, S,kgg<gm<M!
Ngqb!-jugjth<!Ohig<Gl</!!oh{<gTg<G!Ljzh<hijzh<!ohVg<Gl</!
Ouzqh<hVk<kq!
Pergularia extensa 
 Family - Asclepiadace 
 Sju! .!jgh<H!ke<jl!.!ouh<hl<!!hqiqU!.!giIh<H!
osb<G{l<;!
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! Nzqk<!okPf<kOfib<!nk<kje!Bf<kQVNm!
! Ouzqh<!hVk<kqbkqe<!olz<!-jzbiz<!.!Ouozik<Kg<!
! g{<cg<Gl<!uikr<!gMR<se<eq!OkimLl<Ohil<!
! d{<cg<Gl<!uisjebil<!YK/!
! dk<ki!l{qbqjzbiz<!dt<ubqx<Xg<!Ge<loliM!
! Gk<kil<!uzqBr<!GtqVl<Ohil<!hx<xq!
! -sqg<Gl<!uzqbqjvh<Hl<!wk<kch<Hl<!WVl<!
! hsqg<Glkq!lif<kLl<Ohil<!hiI!
! dk<kil{q!OuI,!ogic,!-jz,!hiz<!-jugtqeiz<!osb<k!GcfQjv!yV!
l{<mzl<!dhObigqk<kiz<!szOki]k<kqeiz<!d{<miGl<!uikhqk<k!se<eqgtqe<!
Ohkr<gtie!Oki]uqmr<gt<!biUl<!fQr<Gl</!
&g<gjvs<sije!
BOERHAAVIA REPENS 
Family! .! Nyctagineae!
Sju! .! jgh<H!!
Ke<jl! .! ouh<hl<!
HqiqU! .! gii<h<H!
Osb<jg!
Ogijpbgx<xq! ghavgiiq! Expectorant!
SqXfQi<h<ohVg<gq! Diuretic!
Lzlqtg<gq! Laxative!
Gxqi<s<sqB{<mig<gq! Refrigerant!
HPg<ogiz<zq!Anthelminitic   
 94
ohiKG{l<!
SQk!lgx<Xf<!kqeumg<Gr<!gif<kqkVl<!
Uik!uqjejb!lcg<Gr<gi{<.Ohkq!
OgiMg<Gljk!d{<mig<gix<!OgiltOl!hqk<kl<!
NMg<GOl!&g<Gvm<jm!bib<!
uzqhq{q?!fjls<sz<?!Jbl<?!fQg<Gl<!
Nl{g<G!ofb<!
(Castor Oil) 
Nl{g<G!ofb<bi!zjeui<g<G!L{<Mgzl<!
h,l{g<G!Oleq!HiqGpOz!uib<l{g<g!
ogit<zqz<!ubqXuqMr<!OgivLt<t!uiBuX!
Le<eqz<uV!G{<ll<Ohi!Olii<!
osb<jg;!lzgiiq?!slegiiq!
gicfQi<!
Vinegar of Oryza Satira 
osb<jg;!sQktgiiq?!slegiiq!
hqk<k!lbg<glXl<!OhvU]!kl<LxqBl<!
dx<xhq{q!bqx<sqzju!OliMr<gi{<!sx<Xl<!
upr<gi!usQv{Ll<!ue<OhkqBl<!Ohil<!
hpr<gicg<!Gt<t!hbe<!
hjpjlbijb!gic!szk<kqeiz<!hqk<klbg<gl<?!OsihOvigl<!Lkzqbjugt<!
nsQv{l<?!uikikqsivl<!OhiGl</!
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PRECLINICAL STUDY OF THE DRUG 
QUALITATIVE ANALYSIS OF ACIDIC/BASIC RADICALS AND 
PHYTOCHEMICALCONSTITUENTS IN TEST DRUGS 
Procedure Observation inference 
Test for Calcium: 
2 ml of extract is taken in a clean test 
tube. To this add 2 ml of  4% 
ammonium oxide solution. 
White precipitate is formed Presence of calcium 
Test for Sulphate : 
2 ml of the extract is added to 5 % 
barium chloride solution. 
 White Precipitate is formed Presence of Sulphate 
Test for Chloride :  
The extract is treated with Silver 
nitrate solution 
White precipitate is not 
formed 
Absence of Chloride 
Test for carbonate : 
 The substance is treated with Conc. 
HCl. 
Effervescence is formed Presence of 
carbonate 
Test for Starch : 
 The extract is added with weak 
iodine solution 
Blue colour is not formed Absence of starch 
Test for Iron (Ferric) :  
The extract is treated with glacial 
acetic acid and potassium 
ferrocyanide 
Blue colour is not formed Absence of Ferric 
iron 
Test for Iron (Ferrous) : The extract 
is treated with Conc. HNO3 and 
ammonium thiocynate 
 Blood red colour is formed Presence of Ferrous 
iron 
Test for phosphate :  
The extract is treated with ammonium 
molybdate and conc. HNO3 
Yellow precipitate is  not 
formed 
Abesence of 
phosphate 
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Test for Tannic acid : 
 The extract is treated with Ferric 
chloride 
 
Blue black precipitate is not 
formed 
Abesence of Tannic 
acid 
Test for Unsaturation : 
 1 ml of Potassium permanganate 
solution is added to the extract. 
 
Does not get decolourised Absence of 
unsaturated 
compound 
Test for saponins:  
Dilute extract+ 1ml of distilled water 
shake well. 
 
No Froth formation Abesence of 
saponins 
Test for sugars : 
Benedict method ; 
 5ml of  Benedict solution heated 
gently then add 8 drops of diluted 
extract then heated in a boiling water 
bath. 
 
 colour change 
 
Indicates the Presnce 
of sugar 
Test for steroids :  
Liberman Burchard test ; Dilute 
extract +2 ml acetic 
anhydride+conc.H2SO4 . 
Red colour is not formed Absence of steroids 
Test for amino acids: 
Dilute extract +2ml of Ninhydrin’s 
soln . 
Violet colour is not formed Absence of  amino 
acids 
Test for proteins:  
Biuret method ; 1ml of dilute 
extract+1mlof5%CuSO4+ 
1%NaOH. 
 Violet   colour is not formed Absence of Proteins 
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Test for Flavanoids : 
 Dilute extract+ mg  bits+2drops of 
conc.HCl  and gently heated. 
No formation of pink colour Absence of 
Flavanoids 
Test for phenol; 
 Dilute extract+2drops of FeCl3 soln. 
 Deep green colour is  not 
formed 
Absence of phenols 
Test for Tannins; 
 dilute extract +2ml of 10%lead 
acetate add. 
White precipitate formed Presence of tannins 
Test for alkaloids; 
 Mayer’s method; 1ml of dilute 
extract + 1ml reagent. 
Cream colour precipitate is 
formed 
 
Presence of alkaloids 
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PHARMOCOLOGICAL STUDY 
 
MATERIALS AND METHODS 
Test Drug 
 The following drug was used in the study collected and processed by the methods 
prescribed in standard textbooks of siddha medicines. 
Mirudharsingi Chunnam (MC) 
Mirudharsingi Chunnam was prepared by the method described in (Korakkar 
Santhraregai) 
Preparation of drug for dosing 
 All drugs used for the study was suspended each time with 1% (w/v) solution of 
sodium carboxy methyl cellulose before administration. 
Drugs and chemicals 
! Alloxan monohydrate and fine chemicals used in these experiments were obtained 
from Sigma Chemicals company, U.S.A. Other analytical grade chemicals were obtained 
from S.d. Fine Chemicals Ltd., Mumbai. 
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Experimental animals  
 Colony inbred animals strains of wistar rats of either sex weighing 200 - 250 g 
were used for the pharmacological and toxicological studies. The animals were kept 
under standard conditions 12:12 (day/night cycles) at 220C room temperature, in 
polypropylene cages. The animals were fed on standard pelleted diet (Hindustan Lever 
Pvt Ltd., Bangalore) and tap water ad libitum. The animals were housed for one week in 
polypropylene cages prior to the experiments to acclimatize to laboratory conditions. The 
experimental protocol was approved by the Institutional Animal Ethical Committee 
(IAEC). 
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ANTI INFLAMMATORY STUDY 
Anti inflammatory activity  
 Anti inflammatory activity of MC was evaluated in both acute and chronic models 
of inflammation.  
Acute model 
a. Carrageenan induced hind paw edema  
 The carrageenan assay procedure was carried out according to the method of 
Wintar et al. (1962). Edema was induced by injecting 0.1 ml of a 1% solution of 
carrageenan in saline into the plantar aponeurosis of the left hind paw of the rats.  The 
extracts, reference drug and the control vehicle (distilled water) were administered 60 
min prior to the injection of the carrageenan. The volumes of edema of the injected and 
contra lateral paws were measured at +1, 3 and 5 hrs after induction of inflammation 
using a plethysmometer (Bhatt et al., 1977) and percentage of anti-inflammatory activity 
was calculated.   
Chronic model 
b. Cotton pellet granuloma  
 Sterile cotton pellets (weighing 10 ± 2 mg) were implanted subcutaneously 
along the flanks of axillae and groins of wistar albino rats (Swingle and Shideman et al., 
1972).  The extracts, reference drug and the control vehicle (distilled water) were 
administered as per protocol to rats everyday for a period of 7 days.  On day + 8 the rats 
were sacrificed by cervical decapitation and cotton pellets were removed surgically, freed 
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from extraneous tissue and weighed immediately for wet weight. One half of the pellets 
were dried in an incubator at 60ºC until a constant weight was obtained. 
 
Anti inflammatory activity of (MC) in Cotton Pellet Granuloma 
Groups Cotton pellet Granuloma method 
Dry Weight (mg) 
Control 115.87 ± 15.42 
Test 76.00 ± 10.32** 
Standard (Dic.Sodium  
5 mg/kg/po) 
70.00 ± 7.42** 
n=6; Values are expressed as mean ± S.D followed by One Way Anova using Dunnett’s 
Test 
**P<0.01 as compared with that of control. 
ns – non significant when compared to control groups  
Groups Paw volume (ml) by Mercury Displacement at Regular interval of Time 
0min 30min 60min 120min 240min 
Test 0.901±0.034 1.096±0.077 0.978±0.044 1.38±0.12** 1.22±0.017** 
Standard 
(Dic.Sodium 
5 mg/kg/po) 
0.883±0.063ns 0.996±0.067** 1.02±0.064** 0.926±0.041** 0.896±0.026**
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ANALGESIC ACTIVITY OF (MC) USING EDDY’S HOT 
PLATE METHOD 
Analgesic activity   
Hot plate test 
 The test was performed using Eddy’s hot plate maintained at a temperature of 55 
± 1°C.  The basal reaction time of all animals was recorded.  The animals which showed 
fore paw licking or jumping response within 6-8 secs were selected for the study. 60 min 
after the administration of test and reference compounds, the animals in all the six groups 
were individually exposed to the hot plate maintained at 55°C. The time taken in secs for 
fore paw licking or jumping was taken as reaction time. A cut off period of 15 secs is 
observed to avoid damage to the paws. Analgesic activity was recorded at hourly 
intervals of 2 hours after drug administration 
Groups Paw licking response  (Sec) 
0 min 30 min 60 min 120 min 
Control 7.76±0.96 7.93±0.96 7.86±0.67 8.26±0.53 
Test 7.76±0.98 8.80±0.76 9.80±1.50ns 10.50±1.37* 
Standard 
(Dic.Sodium  
5 mg/kg/po) 
8.43±0.89 8.83±1.16 12.20±1.71** 14.18±1.13** 
n=6,  Values are expressed as mean ± S.D using one way ANOVA followed by Dunnet’s 
method. 
P<0.05 as compared with that of control. 
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ANTI - PYRETIC ACTIVITY 
 Rats selected for the study were fasted overnight allowing water ad libitum. 
Initial rectal temperature was recorded using Hick’s clinical thermometer. Pyrexia was 
induced by subcutaneous injection of TAB vaccine 1 ml/kg body weight.  Six hrs later 
pyrexia was assessed and those animals that did not show a minimum rise of 1.5oC were 
rejected.  The animals thus found fit for the study were divided into 6 groups as described 
above and drugs were administered.  Pyrexia was recorded at hourly intervals for 3 hrs 
after drug administration.  
Antipyretic activity of (MC) using Digital Rectal Thermometer 
Groups Rectal temperature (0C) 
0 min 30 min 60 min 120 min 240 min 
Control 35.90±1.18 37.23±1.24 38.27±0.34 37.20±1.08 36.46±0.88 
Test 35.93±0.20 37.10±0.30 36.33±0.41*** 35.58±0.50* 35.01±0.39* 
Standard 
(Dic.Sodium  
5 mg/kg/po) 
35.80±0.97 36.96±0.95 35.87±0.65*** 35.65±0.60* 35.42±0.52* 
 
n=6,  Values are expressed as mean ± S.D using Student’s paired ‘t’ test. 
P<0.05 as compared with that of control. 
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IN VIVO ANTIOXIDANT STUDY 
Samples of serum collected from  rats treated with test drugs were assayed for 
GSH (Moron et al , 1979)  and LPO (Yagi, 1976)  and the results were compared with  
control group.  
Anti oxidant activity of MC after 21 days repeated oral dosing (500 mg/kg) 
Groups LPO GSH 
Control 0.95 ± 1.37 25.760 ± 0.632 
MC 0.02152±3.90*** 47.721 ± 1.2062*** 
N=6; Values are expressed as mean ± S.D followed by Student T- Test. 
***P<0.001 as compared with control.  
ns – non significant when compared to control groups 
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ACUTE ORAL TOXICITY STUDY     
Acute oral toxicity was conducted as per the OECD guidelines (Organization of 
Economic Cooperation and Development) 423 (Acute Toxic Class Method). The acute 
toxic class method is a stepwise procedure with 3 animals of a single sex per step. 
Depending on the mortality and /or moribund status of the animals, on the average 2-4 
steps may be necessary to allow judgment on the acute toxicity of the test substance. This 
procedure results in the use of a minimal number of animals while allowing for 
acceptable data based scientific conclusion. 
The method uses defined doses (5, 50, 300, 2000 mg/kg body weight) and the 
results allow a substance to be ranked and classified according to the Globally 
Harmonized System (GHS) for the classification of chemicals which cause acute toxicity 
Wistar albino rats of either sex weighing 200-250 g were fasted overnight, but 
allowed water ad libitum. Since the formulation is relatively non toxic in  clinical practice 
the highest dose of 2000 mg/kg/p.o (as per OECD guidelines “Unclassified”) was used in 
the acute toxicity study.   
The animals were observed closely for behavioural toxicity, if any by using FOB 
(Functional observation battery). 
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REPEATED ORAL TOXICITY STUDY 
Repeated oral toxicity studies can be used to get additional information regarding 
the toxicity profile of a chemical. Repeated oral toxicity studies are defined as those 
studies where the chemical is administered to the animal for a period covering 
approximately 10% of the expected life of the animal. Usually, the dose levels are lower 
than for acute studies and allow chemicals to accumulate in the body before lethality 
occurs, if the chemical possess this ability. 
Experimental procedure 
The following experimental procedure was followed to evaluate the repeated oral 
toxicity study of  
1. Mirudharsingi Chunnam (MC) 
Group I : Control animals received 1% tween 20, 2 ml/kg/p.o. for 21  days  
Group II : Mirudharsingi Chunnam (MC) with ghee at the dose Level of 500 
mg/kg/p.o.  for 21 days 
 Body weight, food intake and water intake was recorded at two intervals with 
simultaneous observation for toxic manifestation and mortality, if any. At the end of 21 
days treatment all the animals were sacrificed by over dosage of ether anaesthesia. Blood 
was collected and used for haematological studies. Section of liver, kidney, and heart 
were dissected out and kept in 10% formalin for histopathological studies 
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Effect of Siddha Formulations (MC) on Haematological parameters after 21 days repeated oral dosing (500 mg/kg) 
Groups Hb (gm/100ml) RBC (millions/cu.mm)
Control  14.45±0.4113 5.20±0.047 
Test  13.92±2.22ns 4.183±0.4262** 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
***P<0.001 as compared with that of control.   
ns – non significant when compared to control groups 
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Effect of Siddha formulation (MC) on Biochemical markers of liver and kidney after 21 days repeated oral dosing (500 
mg/kg/po) in rats  
 
 
Groups ALP 
(K.A.Units) 
AST  
(IU/L) 
 
ALT  
(IU/L) 
 
Urea 
(mg/100ml) 
BUN 
(mg/ 100ml) 
Glucose mg/dl Cholesterol 
mg/dl 
Control 2.973±0.3929 79.89±1.906 25.48±2.93 16.38±2.12 7.52±0.84 83.57±6.97 53.75±6.90 
Test 3.667±0.4719 * 157.2±3.920 *** 17.08±0.80 *** 17.03±0.187 ns 7.90±0.11ns 86.27±11.47ns 59.78±3.20 ns 
N=6; Values are expressed as mean ± S.D followed by Students Paired ‘T’ Test 
***P<0.001 as compared with that of control.   
ns – non significant when compared to control
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Results 
Preliminary basic, acidic radicals and phytochemical studies   
The qualitative chemical analysis and acidic, basic radicals assay of the drugs 
showed the presence of phytoconstituents and minerals as depicted in (Table 1). 
 Acute oral toxicity study 
MC at the dose of 2000mg/kg/po did not exhibit any mortality in rats. As per 
OECD 423 guidelines the dose is said to be “Unclassified” under the toxicity scale. 
Hence further study with higher doses was not executed.  
Repeated oral toxicity for 21 days 
Test drug MC at the dose of 500 mg/kg/po when administered orally for 21 
days in rats did not show toxicity in renal functions. However the drug exhibited 
significant reduction in RBC count and elevation of marker enzyme levels of liver 
(Table 2 and 3). 21 days repeated dosing of the drug did not exhibit change in the 
serum glucose and cholesterol levels (Table 3). 
Histopathological study 
MC at the dose of 500 mg/kg/po daily administered for 21 days did not show 
evidence of pathological lesions in the tissues tested (Plate 1). 
Analgesic, Antiinflammatory and Antipyretic studies  
MC at the dose of 500 mg/kg/p.o showed significant analgesic, antipyretic 
activity in rats(Table 7,8). MC also exhibited significant anti-inflammatory activity in 
both carrageenan induced hind paw (acute inflammation model) and cotton pellet 
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granuloma (chronic inflammation model) models of inflammation in rats. The results 
of present study was comparable to that of the standard NSAID Diclofenac sodium (5 
mg/kg/p.o) (Table 4,5). 
Antioxidant activity  
At the end of 21 days repeated oral toxicity study when the plasma of drug 
treated animals was examined for GSH activity, the level of GSH activity was 
increased significantly (p>0.001) in test groups. On the other hand the LPO activity 
was considerably reduced in drug treated group when compared to control (Table 6). 
Discussion 
The siddha formulation MC was tested for its reverse pharmacological and 
toxicological profiles in the experimental rats. The drug did not exhibit mortality at 
the dose of 2000 mg/kg/p.o, hence further test was not conducted with higher doses. 
According to OECD 423 guidelines, the substances did not exhibit mortality at the 
dose of 2000 mg/kg/p.o and above are “Unclassified” in the toxicity scale. 
The preliminary phytochemical study revealed the presence of alkaloids and 
tannins in the test drug. The test drug also answered for the presence of Ca++, Fe++, 
sulphate and carbonate. 
The repeated oral toxicity study conducted for 21 days with the drug did 
exhibit significant reduction (P<0.01) in RBC count without significant change in 
Hb%, similarly the test drug exhibited significant (P<0.001) alteration in liver marker 
enzymes levels (AST and ALT) with lesser significant (P<0.05) effect on ALT. 
However, these alterations did not reflect on the histopathological study of liver tissue 
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after 21 days repeated dosing. There was no significant changes in Haematological 
parameters like blood sugar, Cholesterol, body weight, food, water intake and 
behavioural parameters. However the drug did not exhibit any alteration in the 
function of kidney after repeated oral dosing for 21 days. 
The test drug exhibited significant analgesic, antipyretic and anti-
inflammatory activity in both acute and chronic experimental inflammatory 
conditions in rats. In cotton pellet granuloma the test drug (500 mg/kg/p.o) exhibited 
significant (P<0.01) anti-inflammatory activity which was comparable to that of 
Diclofenac Sodium (5 mg/kg/p.o). A similar result was also obtained with the test 
drug in carrageenan induced hind paw edema model. The test drug showed maximum 
anti-inflammatory activity at the end of 4th hour after carrageenan challenge. The 
result of test drug (500 mg/kg/p.o) was comparable to that of Diclofenac Sodium ( 5 
mg/kg/p.o). Since the maximum anti-inflammatory activity (reduction in the paw 
edema volume) was observed at the end of 4th hour, the mechanism of anti-
inflammatory activity of test drug may be attributed for its inhibitory activity on 
cyclooxygenase (COX) enzymes. 
The present study on the reverse pharmacological and toxicological profiles of 
the drug may be summarized as follows : 
1. The drug is relatively safe since it exhibited no mortality even at the 
dose of 2000mg/kg/p.o 
2. Though the repeated drug treatment for 21 days exhibited alteration in 
the liver function tests, the test drug did not exhibit any alterations in 
the normal architecture of the liver at the end of 21 days. Since there 
is no report on the LFT done in clinical study, it can be reasonably 
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assumed that the drug is safe for humans unless and otherwise proved 
with clinical data generated on  LFT. 
3. The reduction in RBC count on repeated administration for 21 days 
may be accounted for high level of lead (Pb) in the preparation (not 
reported). 
4. The present experimental study exhibits a good correlation between 
clinical efficacy of drug vis-a-vis reverse pharmacological test results. 
5. Further, on the evidence of reverse pharmacological studies Liver 
function tests (LFT) should be made mandatory in patients receiving 
the drug for a longer duration with titration of doses to get maximum 
clinical efficacy. 
6. The formulation exhibited significant antioxidant and inhibition of 
LPO in rats treated for 21 days 
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CONSENT FORM 
Certificate by Investigator 
 I certify that I have disclosed all details about the study in the terms readily 
understood by the Patient. 
Date :__________________     Signature ____________ 
       Name _________________ 
Consent by Patient 
 I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow – up 
including the laboratory investigations to be performed to monitor and safeguard my 
body functions.  
 I am aware of my right to opt out of the trial at any time during the course of 
the trial without having to give the reasons for doing so. 
 I, exercising my free power of choice, hereby give my consent to be included 
as a subject in the clinical trial of “Mirutharsingi Chunnam and Poochu Ennai”  
for the management Azhal Keel Vaayu (OsteoArthritis)  
Date:      Signature 
      Name: 
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HAEMATOLOGICAL REPORT FOR 60 PATIENTS 
 
S.
N
O 
IP
NO NAME 
A
G
E 
S
E
X 
1ST DAY 24TH DAY 48TH DAY 
TC 
CELLS/C
UMM 
DC% ESR TC/ 
CELLS/ 
CUMM 
DC% ESR TC 
CELLS/CU
MM 
DC% ESR 
P% L% E% ½ HR 1 HR P% L% E% ½ HR 1 HR P% L% E% ½ 
HR 
1 HR 
1 454 SENTHAMARAI 6
7 
M 7800 58 40 2 17 36 7800 56 40 2 12 24 7900 56 40 2 6 12 
2 186 JOTHI 4
9 
F 7800 50 48 2 24 38 7900 54 42 2 14 34 7800 50 49 2 14 20 
3 455 NARAYANAN 7
0 
M 7600 50 46 4 35 72 7800 59 40 4 26 52 7900 60 58 2 8 16 
4 194 JAYALAKSHMI 5
0 
F 9000 54 40 6 12 26 8800 54 40 2 10 22 8900 56 42 2 8 16 
5 198 NAGAMAL 5
8 
F 8100 50 40 6 12 26 9000 50 40 4 8 16 9200 50 40 4 6 12 
6 475 BOOPTHAY 6
0 
M 8100 50 40 6 12 26 9000 50 40 4 8 16 9200 50 40 4 6 12 
7 482 ABDUL JHADER 5
2 
M 7600 54 42 4 14 28 9600 52 40 2 6 12 7800 54 40 2 6 12 
8 207 SAGUNTHALA 4
6 
F 7900 54 44 4 18 26 8800 52 44 4 12 24 8800 56 40 4 10 20 
9 481 CHINNAKANNU 5
1 
M 7800 56 40 4 8 10 8200 54 42 2 6 12 8500 56 46 2 4 8 
10 223 PADMAVATHI 6
5 
F 8000 60 40 2 18 38 8100 58 46 2 16 32 8200 60 48 2 8 16 
11 498 GANESAN 5
6 
M 8800 58 48 4 9 18 8800 58 40 2 4 10 8900 56 46 2 4 8 
12 507 SELVAM 4
0 
M 7200 54 42 4 10 20 8000 54 42 2 6 12 8300 50 42 2 4 10 
13 509 BALU 5
1 
M 7500 54 42 2 6 12 7800 50 42 4 4 8 7800 58 48 2 2 4 
14 510 KARUPPAN 5
5 
M 7800 58 40 2 10 20 8000 56 46 2 8 16 8600 58 44 2 8 16 
15 515 PERUMAL 5
0 
M 7300 56 40 4 6 12 8000 55 40 2 3 6 8200 54 40 2 2 4 
16 241 CHANDARA 5
5 
F 7800 60 46 4 12 26 7900 56 40 4 10 22 7900 58 44 2 8 16 
17 246 LALITHA BAI 6
5 
F 7000 56 38 6 12 24 7800 56 40 4 8 16 7800 58 40 4 4 10 
18 530 BASAVARAJAN 7
0 
M 6800 56 40 2 8 16 6900 56 44 2 8 16 6800 54 44 2 6 12 
19 251 MAYAVADHI 5
0 
F 7300 56 40 4 18 36 7400 56 40 2 12 24 7600 56 44 2 10 20 
20 257 YAMUNA BAI 5
3 
F 8100 59 39 2 14 28 8300 56 48 2 13 26 8700 54 40 2 10 20 
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S. 
NO OPNO NAME 
AG
E SEX 
1ST DAY 24TH DAY 48TH DAY 
TC 
CELLS/CU
MM 
DC% ESR TC/ 
CELLS/ 
CUMM 
DC% ESR TC 
CELLS/CU
MM 
DC% ESR 
P% L% E% ½ HR 1 HR P% L% E% ½ HR 1 HR P% L% E% ½ HR 1 HR 
21 S510 K.SANTHANAM 63 M 6900 50 46 4 12 26 7300 48 45 4 6 14 7300 50 44 2 6 12 
22 S1205 MUTHULAKSHMI 53 F 8000 54 44 2 8 16 8400 56 42 2 6 12 8400 52 44 2 5 10 
23 S2585 LOGANATHAN 60 M 7800 58 36 6 4 8 7900 56 40 4 4 8 7900 48 42 2 4 8 
24 S2861 RAJAKUMARI 43 F 8700 54 40 4 6 12 8800 50 42 4 5 10 8900 54 42 4 5 10 
25 S2973 SAKUM\NTHALA 57 F 6000 54 40 6 8 14 6000 48 50 2 6 14 6200 50 48 2 6 12 
26 M9760 SEENU 55 F 7700 52 46 8 5 10 7800 50 44 4 5 10 7800 52 44 2 4 18 
27 S6119 SANTHYA 44 F 7400 50 44 6 8 16 7400 50 44 4 8 16 7200 50 46 2 5 10 
28 S7163 RAMILA 42 F 9000 60 40 2 4 8 8900 58 44 2 4 8 8900 58 44 2 4 8 
29 S9410 SANMUGAVALLI 58 F 8400 54 40 6 16 32 8400 56 42 6 12 24 8300 56 42 4 8 16 
30 S9944 RAJU 65 M 7200 58 40 2 4 8 7200 58 40 2 4 8 7600 56 40 2 4 8 
31 S9802s UNAMALAI 47 F 7700 54 40 6 12 26 7800 54 44 6 10 20 7800 56 40 4 6 12 
32 T270 DHAKSHANAMURTHY 61 M 8000 58 38 4 9 12 8100 60 40 2 6 12 8200 56 40 2 2 4 
33 T1935 RAJENDERAN 52 M 8200 56 48 4 2 4 8600 54 46 2 2 4 8700 56 48 2 2 4 
34 T2034 TULASI 65  8900 58 49 4 12 24 8800 56 48 2 10 20 8900 56 48 2 8 16 
35 T2529 JANABAI 50 M 7800 56 40 4 8 22 7800 54 40 2 8 16 7800 54 40 2 8 16 
36 T3015 PONNAMMAL 50 F 8400 48 40 2 5 10 8200 48 46 2 5 10 8700 48 40 2 5 10 
37 T4330 VIJAYLAKSHMI 52 F 8100 60 40 2 4 10 8000 58 42 2 8 16 8100 56 42 2 8 16 
38 T4521 KAUSHALYA 55 F 7200 56 40 4 12 25 7100 54 42 2 10 20 7200 50 40 2 8 16 
39 T5524 RAJAMANI 59 F 8700 50 46 4 8 16 8900 56 46 4 8 16 8600 50 46 2 6 12 
40 T5766 ARUMUGAM 46 M 8000 56 36 4 2 4 8000 56 36 4 2 4 8200 56 36 2 2 4 
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S. 
NO OPNO NAME 
AG
E SEX 
1ST DAY 24TH DAY 48TH DAY 
TC 
CELLS/CU
MM 
DC% ESR TC/ 
CELLS/ 
CUMM 
DC% ESR TC 
CELLS/CU
MM 
DC% ESR 
P% L% E% ½ HR 1 HR P% L% E% ½ HR 1 HR P% L% E% ½ HR 1 HR 
41 T6419 RAJI 50 F 7800 58 42 4 10 22 7600 58 40 2 8 16 7600 58 40 2 8 16 
42 T7414 MARIAMMAL 63 F 7300 52 46 4 10 22 7200 52 46 2 2 16 7400 50 46 2 8 16 
43 T8561 RAJ KUMAR 48 F 8800 56 38 2 10 22 8700 54 38 4 8 16 8600 54 36 2 6 12 
44 T8605 MOHANRAJ 59 M 8800 56 40 2 4 8 8900 56 40 2 8 8 8800 56 40 2 4 8 
45 T8665 PUSHPA RANI 56 M 9200 52 40 6 10 22 8900 50 38 2 8 16 8900 50 40 2 8 16 
46 T8904 YETHIRAJULU 78 F 9600 56 40 4 6 12 9500 54 40 2 4 12 9500 54 40 4 6 12 
47 T9225 MANIKAM 65 M 8100 58 48 8 6 12 7900 49 44 4 8 12 7900 48 46 2 6 12 
48 T9020 VALLI 47 F 7500 52 42 4 10 20 7600 43 42 6 6 12 7700 40 42 2 6 12 
49 U1095 CHANDRAPILLAI 59 F 7100 54 40 4 25 54 7000 52 42 2 10 20 7000 54 44 2 8 16 
50 U1136 KANNIA 50 F 8200 50 46 4 10 20 8100 50 46 2 8 16 8000 56 46 2 8 16 
51 U1494 THIRUNAUKARAS
U 
69 M 6800 56 40 6 8 16 6700 56 42 4 6 12 6900 56 40 2 6 12 
52 S7163 KANNATAHL 55 F 8700 56 42 4 16 32 8600 52 42 2 12 24 8500 54 40 2 8 16 
53 U6091 KANCHANA 52 F 8700 59 39 4 14 30 8600 58 38 2 8 16 8500 58 38 4 6 12 
54 U6499 DAHANALAKSHM
I 
62 F 8800 56 40 4 14 20 8900 56 42 4 10 20 8900 50 40 2 6 12 
55 U7214 DHARMARAJAN 62 M 8700 52 48 2 12 24 8600 54 48 4 10 20 8500 52 48 2 8 16 
56 U7552 KASTURI 55 F 7800 58 36 4 18 38 7800 50 34 2 12 24 7900 56 34 2 10 20 
57 U8708 ALAMELU 50 F 7800 50 44 4 10 22 7600 50 42 2 8 16 7600 48 40 4 6 12 
58 U8566 ALLAPICHAI 60 M 7900 48 48 6 12 24 7800 48 46 2 8 16 7700 49 48 2 6 12 
59 T7348 SARASWATHI 55 F 7000 58 40 6 13 26 7000 58 40 2 10 20 6900 56 40 2 8 16 
60  FATHIMA 45 F 7000 50 42 2 10 20 7100 46 42 2 8 16 7000 40 42 2 6 12 
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                                                          FIRST DAY      24TH DAY      49TH DAY 
SI NO IP 
NO 
NAME A 
G  
E 
S 
E 
X 
BLOOD SUGAR  BLOOD SUGAR  BLOOD SUGAR  
F PP R Hb TRBC Urea S. 
creatin 
S. chol F PP R Hb TRBC Urea S. 
creat 
S chol F PP R Hb TRBC Urea S. 
creat 
S. chol 
     Mg% Mg% Mg
% 
% MillionCe
lls/ Cumm
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionCe
lls/ 
Cumm 
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionC
ells/ 
Cumm 
Mg% Mg% Mg% 
1 454 SENTHAMARAI 67 M 126 215  13 4.5 42 0.8 167 110 170  14 4.5 39 0.8 160 114 200  15 4.8 40 0.8 170 
2 186 JOTHI 49 F 74 126  11.6 3.8 30.2 1.2 156 81.4 141  11.6 3.8 31 0.8 178 80 120  11.6 4.0 27 0.8 160 
3 455 NARAYANAN 70 M 90 141  12 4.5 40 1.1 172 84 110  12 4.8 35 0.8 180 90 121  13.4 5.2 31 0.8 164 
4 194 JAYALAKSHMI 50 F 96.2 126  12.2 4.3 35 1.2 174 74 79  12.6 4.4 32 1.2 180 74 120  12.8 4.8 32 0.8 178 
5 198 NAGAMAL 58 F 181.4 244  12.8 3.5 29 1.1 181 130 160  13.2 3.9 22 0.8 183 120 160  13.2 4.2 22 0.8 161 
6 475 BOOPTHAY 60 M 107 156  12 5.2 39 0.9 200 71 114  12.8 5.2 30 0.8 208 92 120  13 5.4 30 0.8 172 
7 482 ABDUL JHADER 52 M 78 96  12.2 4.8 41.4 0.8 150 84 112  11.8 5.2 40 0.8 165 90 112  12.2 5.3 40 0.6 185 
8 207 SAGUNTHALA 46 F 72 112  12 3.8 24.4 0.6 165 77 110  14 4.0 19 0.8 241 80 110  14 4.1 29 0.8 170 
9 481 CHINNAKANNU 51 M 93 111  11.8 5.2 23 1.2 163 86 110  12.4 5.3 22 0.8 174 90 120  13.5 5.3 24 0.8 175 
10 223 PADMAVATHI 65 F 99 184  10.8 4.1 19 0.9 208 91 161  10.8 4.2 19 0.9 200 96 128  11 4.8 20 0.8 174 
11 498 GANESAN 56 M 86 176  14 4.2 38 0.6 207 67 130  14.6 4.2 37 0.8 210 90 136  14.8 4.4 30 0.8 200 
12 507 SELVAM 40 M 70 118  13 4 26 0.8 288 74 110  13 4.1 26 0.8 188 90 120  13.6 4.1 18 0.8 210 
13 509 BALU 51 M 70 104  14.2 3.8 26 0.9 140 80 110  14 3.8 26 0.9 138 80 120  14.6 4.0 20 0.8 128 
14 510 KARUPPAN 55 M 108 220  12 4.2 34 0.9 135 100 230  12.6 4.3 26 0.9 155 100 126  12.6 4.3 26 0.7 153 
15 515 PERUMAL 50 M 84 96  13 4.4 41 0.8 130 92 109  13.2 4.4 29 0.8 140 90 106  13.6 4.5 21 0.8 130 
16 241 CHANDARA 55 F 74 110  11 3.8 18 1.0 126 68 125  12.2 3.8 18 0.8 171 68 125  12.6 4.0 18 0.8 171 
17 246 LALITHA BAI 65 F 86 168  11 4.0 20 1.2 163 93 118  12.6 4.0 20 0.8 143 93 118  12.6 4.0 20 0.8 163 
18 530 BASAVARAJAN 70 M 89 107  12.2 3.5 19 1.0 155 90 100  12.6 3.8 17 1.0 155 97 110  12.4 3.8 17 1.0 180 
19 251 MAYAVADHI 50 F 90 138  12.4 3.8 26 0.8 126 70 108  12.4 3.7 24 0.8 126 98 140  12.6 3.9 20 0.8 130 
20 257 YAMUNA BAI 53 F 81 100  13.2 3.6 18 0.9 223 76 128  14.8 3.6 18 0.9 170 96 138  14.2 3.6 18 0.9 230 
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FIRST DAY      24TH DAY      49TH DAY 
SI NO OP 
NO 
NAME A G 
E 
S 
E 
X 
BLOOD SUGAR  BLOOD SUGAR  BLOOD SUGAR  
F PP R Hb TRBC Urea S. 
creatin 
S. chol F PP R Hb TRBC Urea S. 
creat 
S chol F PP R Hb TRBC Urea S. 
creat 
S. chol 
     Mg% Mg% Mg
% 
% MillionCe
lls/ Cumm
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionCe
lls/ 
Cumm 
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionC
ells/ 
Cumm 
Mg% Mg% Mg% 
21 S510 k.santhanam 63 M 96.2 107.4  12.8 4.0 36 1.2 189 107 130  13.4 4.0 36 1.2 109 130 100  13.8 4.0 35 0.8 120 
22 S1205 Muthulakshmi 53 F   119 10.8 3.5 40 12 232   124 11.6 3.5 38 0.8 188   108 11.6 3.5 38 0.8 176 
23 S2585 Loganathan 60 M   107 10.2 3.5 39 0.9 120   100 11.0 3.5 38 0.9 125   102 11.0 3.5 38 0.9 120 
24 S2861 Rajakumari 43 F 120 120  10.8 3.8 25 0.8 152 78 100  11 3.8 23 0.5 160 80 110  11.6 3.6 20 0.9 148 
25 S2973 Sakum\nthala 57 F 141 141  9.8 3.7 26 1.2 210 86 110  12.5 3.6 26 1.2 220 86 110  12.5 3.6 25 1.0 180 
26 M9760 Seenu 55 F 128 128  13 3.9 23 0.9 134 90 130  13 3.9 23 0.9 230 89 120  12.8 3.8 23 0.9 150 
27 S6119 Santhya 44 F 89 89  12.2 3.6 25 0.8 135 80 110  12.2 3.6 23 0.9 125 86 120  12.2 3.6 23 0.8 160 
28 S7163 Ramila 42 F   110 10.6 3.4 8 0.8 128   106 11 3.4 8 0.9 120   100 10.6 3.5 08 0.6 140 
29 S9410 Sanmugavalli 58 F 252 252  10.8 4.1 18 1.2 172 128 240  10.8 4.1 18 0.9 132 124 250  10.8 4.3 18 0.8 180 
30 S9944 Raju 65 M   244 11.8 4.0 28 1.3 236   220 12.8 4.8 28 1.0 230   210 13 4.9 28 1.1 220 
31 S9802s Unamalai 47 F 115 115  11.8 3.3 18 0.9 140 74 120  11.8 3.3 18 1.2 140 80 110  11.6 3.2 17 1.0 150 
32 T270 Dhakshanamurthy 61 M 114 114  12.2 4.7 18 1.1 155 90 120  12.4 4.7 20 0.9 155 81 148  12.6 4.7 21 0.8 160 
33 T1935 Rajenderan 52 M 163 163  12.8 5.0 21 0.8 180 130 163  12.8 5.0 21 0.8 180 80 120  12..2 5.2 20 0.9 189 
34 T2034 Tulasi 65  178 178  12 4.3 22 0.9 190 96 180  12.4 4.8 22 0.8 180 96 170  12.6 4.8 20 0.8 170 
35 T2529 Janabai 50 M   80 12.8 3.9 18 0.9 173   96 12.8 3.8 18 1.0 170   96 12.8 3.9 18 1.0 180 
36 T3015 Ponnammal 50 F 104 104  11.2 4.0 18 0.8 142 86 110  12.2 3.9 18 0.8 140 80 120  11.2 3.9 18 0.9 130 
37 T4330 Vijaylakshmi 52 F 90 138  10 4.1 16 0.9 200 94 140  10 4.0 16 1.0 210 88 110  10.4 4.0 16 0.9 200 
38 T4521 Kaushalya 55 F   80 11.4 3.9 21 1.0 220   86 1.4 3.8 21 0.9 225   98 11.8 3.8 21 0.9 220 
39 T5524 Rajamani 59 F 93 173  11.4 4.0 17 0.8 163 96 150  11.6 4.0 17 0.7 160 98 140  11.8 4.0 17 0.9 140 
40 T5766 Arumugam 46 M 86 138  10.8 3.8 28 0.8 193 86 160  10.8 3.8 24 0.8 198 86 166  10.8 3.8 27 0.7 180 
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SI NO OP 
NO 
NAME A G 
E 
S 
E 
X 
BLOOD SUGAR  BLOOD SUGAR  BLOOD SUGAR  
F PP R Hb TRBC Urea S. 
creatin 
S. chol F PP R Hb TRBC Urea S. 
creat 
S chol F PP R Hb TRBC Urea S. 
creat 
S. chol 
     Mg% Mg% Mg
% 
% MillionCe
lls/ Cumm
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionCe
lls/ 
Cumm 
Mg% Mg% Mg% Mg% Mg% Mg
% 
% MillionC
ells/ 
Cumm 
Mg% Mg% Mg% 
41 T6419 RAJI 50 F 83 97  13.8 3.8 24 0.6 218 86 100  13.8 3.8 24 0.7 210 90 110  13.8 3.8 16 1.0 200 
42 T7414 MARIAMMAL 63 F 99 110  11.6 3.5 25 0.8 207 92 120  11.6 3.4 24 0.9 200 90 120  12. 3.4 21 0.7 200 
43 T8561 RAJ KUMAR 48 F 84 107  12.2 3.6 24 0.8 170 90 110  12.2 3.5 24 0.6 180 89 120  12.2 3.5 17 0.8 180 
44 T8605 MOHANRAJ 59 M   82 12.4 3.7 27 0.6 190   82 12.4 3.9 27 0.6 190   90 12.8 3.9 27 0.9 170 
45 T8665 PUSHPA RANI 56 M 82 150  12.6 4.0 18 0.7 163 86 126  12.4 4.1 18 0.6 150 90 142  12.6 4.0 24 0.7 160 
46 T8904 YETHIRAJULU 78 F 125 186  12.8 4.1 31 0.8 160 120 160  10.2 4.0 31 0.9 165 110 140  10.4 4.0 25 0.8 170 
47 T9225 MANIKAM 65 M   122 11.8 3.9 25 0.9 180   120 12.8 4.0 25 0.9 180   110 12 3.8 24 0.9 180 
48 T9020 VALLI 47 F 86 104  13.2 3.5 21 0.9 180 78 98  11.7 3.4 20 1.0 165 75 100  11.8 3.5 27 1.0 170 
49 U1095 CHANDRAPILLAI 59 F 86 117  11.2 4.1 18 1.2 150 86 120  13.2 4.0 18 0.9 160 90 100  13.2 4.1 18 0.8 150 
50 U1136 KANNIA 50 F 76 121  10.4 3.8 21 0.9 165 80 120  11.2 3.9 20 1.0 160 90 136  11.2 4.0 30 1.1 165 
51 U1494 THIRUNAUKARAS
U 
69 M 118 167  11.2 4.2 23 1.2 160 110 140  11.4 4.2 20 1.2 170 106 136  11.8 4.0 26 1.1 110 
52 S7163 KANNATAHL 55 F 118 167  10.4 4.2 23 1.2 160 110 140  11.4 4.2 20 1.2 170 106 120  11.8 4.0 20 0.8 170 
53 U6091 KANCHANA 52 F 92 156  10.4 40 26 0.8 220 90 130  10.4 4.1 26 0.9 240 86 140  10.4 4.0 18 0.9 230 
54 U6499 DAHANALAKSHM
I 
62 F 113 186  10.6 3.5 20 0.9 200 110 150  11.6 3.5 20 0.9 190 102 135  11.6 3.5 21 0.8 190 
55 U7214 DHARMARAJAN 62 M 110 157  11.6 4.0 30 0.8 192 109 145  12.4 3.9 20 0.8 190 96 220  11.8 4.0 20 0.7 190 
56 U7552 KASTURI 55 F 107 216  12.4 3.8 28 0.8 180 100 200  11.4 3.8 20 0.8 198 110 120  12.8 3.8  0.9 198 
57 U8708 ALAMELU 50 F 77 117  11.4 4.0 24 0.8 288 86 120  9.4 4.1 20 0.8 290 89 120  11.8 4.0 20 1.1 290 
58 U8566 ALLAPICHAI 60 M 86 100  8.6 3.9 24 1.2 200 90 107  11.0 4.0 24 1.0 220 80 120  9.8 4.1 24 0.9 230 
59 T7348 SARASWATHI 55 F 90 120  10.6 4.0 20 1.2 200 96 110  11 4.0 20 0.9 180 90 100  10.4 3.9 20 1.0 184 
60  FATHIMA 45 F 95 110  9.4 3.5 23 1.0 180 86 100   3.4 19 0.7 160 80 100  10 3.4 20 1.0 150 
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 URINE ANALYSIS 
 
S.NO IPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
Alb Sug DEPOSITS Alb Sug DEPOSITS Alb Sug ESR 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
1 454 SENTHAMARAI 67 M Nil + 2-3 2-3 Nil Nil Nil + 4-6 2-4 Nil Nil Nil Nil 4-6 2-4 Nil Nil 
2 186 JOTHI 49 F Nil Nil 2-4 2-4 Nil Nil Nil Nil 4-6 4-6 Nil Nil Nil Nil 2-3 2-4 Nil Nil 
3 455 NARAYANAN 70 M Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 5-6 5-6 Nil Nil 
4 194 JAYALAKSHMI 50 F Nil Nil 4-6 4-6 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
5 198 NAGAMAL 58 F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
6 475 BOOPTHAY 60 M Nil Nil 2-4 2-5 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
7 482 ABDUL JHADER 52 M Nil Nil 2-3 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
8 207 SAGUNTHALA 46 F Nil Nil 4-6 4-6 Nil Nil Nil Nil 2-4 1-2 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
9 481 CHINNAKANNU 51 M Nil Nil 2-3 2-3 Nil Nil Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-5 Nil Nil 
10 223 PADMAVATHI 65 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-3 4-5 Nil Nil 
11 498 GANESAN 56 M Nil Nil 4-6 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
12 507 SELVAM 40 M Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
13 509 BALU 51 M Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
14 510 KARUPPAN 55 M Nil ++ 3-4 4-6 Nil Nil Nil + 2-4 3-4 Nil Nil Nil + 1-2 2-4 Nil Nil 
15 515 PERUMAL 50 M Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-4 2-4 Nil Nil 
16 241 CHANDARA 55 F Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
17 246 LALITHA BAI 65 F Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-3 Nil Nil 
18 530 BASAVARAJAN 70 M Nil Nil 2-3 2-6 Nil Nil Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
19 251 MAYAVADHI 50 F Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
20 257 YAMUNA BAI 53 F Nil Nil 2-4 2-5 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
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S.NO IPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
Alb Sug DEPOSITS Alb Sug DEPOSITS Alb Sug ESR 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
21 S510 K.SANTHANAM 63 M Nil Nil 1-2 2-4 Nil Nil Nil + 1-2 2-4 Nil Nil Nil Nil 2-4 4-6 Nil Nil 
22 S1205 MUTHULAKSHMI 53 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 5-6 Nil Nil 
23 S2585 LOGANATHAN 60 M Nil Nil 4-6 5-6 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 4-6 Nil Nil 
24 S2861 RAJAKUMARI 43 F Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-4 2-4 Nil Nil 
25 S2973 SAKUM\NTHALA 57 F Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 4-6 Nil Nil 
26 M9760 SEENU 55 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 3-4 Nil Nil 
27 S6119 SANTHYA 44 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
28 S7163 RAMILA 42 F Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
29 S9410 SANMUGAVALLI 58 F Nil Nil 3-4 2-4 Nil Nil Nil Nil 1-2 1-2 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
30 S9944 RAJU 65 M Nil ++ 1-2 2-4 Nil Nil Nil ++ 2-4 2-4 Nil Nil Nil + 2-4 3-4 Nil Nil 
31 S9802s UNAMALAI 47 F Nil Nil 1-2 1-2 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
32 T270 DHAKSHANAMURT
HY 
61 M Nil Nil 2-3 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
33 T1935 RAJENDERAN 52 M Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 4-5 Nil Nil 
34 T2034 TULASI 65  Nil Nil 2-4 3-4 Nil Nil Nil + 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
35 T2529 JANABAI 50 M Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 2-3 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
36 T3015 PONNAMMAL 50 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
37 T4330 VIJAYLAKSHMI 52 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
38 T4521 KAUSHALYA 55 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-3 2-4 Nil Nil 
39 T5524 RAJAMANI 59 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
40 T5766 ARUMUGAM 46 M Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
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S.NO OPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
Alb Sug DEPOSITS Alb Sug DEPOSITS Alb Sug ESR 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
Pus 
cells 
Epi 
.cells 
RBC’s Casts/ 
crystals 
41 T6419 RAJI 50 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
42 T7414 MARIAMMAL 63 F Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
43 T8561 RAJ KUMAR 48 F Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 3-4 4-6 Nil Nil 
44 T8605 MOHANRAJ 59 M Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 1-2 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
45 T8665 PUSHPA RANI 56 M Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 3-4 Nil Nil 
46 T8904 ETHIRAJULU 78 F + + 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
47 T9225 MANIKAM 65 M Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
48 T9020 VALLI 47 F Nil Nil 2-4 4-5 Nil Nil Nil Nil 2-4 4-6 Nil Nil Nil Nil 3-5 4-5 Nil Nil 
49 U1095 CHANDRAPILLAI 59 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
50 U1136 KANNIA 50 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 3-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
51 U1494 THIRUNAUKARASU 69 M Nil + 1-2 2-4 Nil Nil Nil + 2-4 3-4 Nil Nil Nil + 1-2 2-4 Nil Nil 
52 S7163 KANNATAHL 55 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
53 U6091 KANCHANA 52 F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
54 U6499 DAHANALAKSHMI 62 F Nil + 2-4 3-4 Nil Nil Nil + 1-2 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
55 U7214 DHARMARAJAN 62 M Nil Nil 2-4 3-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
56 U7552 KASTURI 55 F Nil + 2-4 4-5 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
57 U8708 ALAMELU 50 F Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 4-6 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
58 U8566 ALLAPICHAI 60 M Nil Nil 2-4 3-4 Nil Nil Nil Nil 1-2 3-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
59 T7348 SARASWATHI 55 F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
60  FATHIMA 45 F Nil Nil 2-4 1-2 Nil Nil Nil Nil 3-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
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STOOLS EXAMINATIONS 
 
S.NO IPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
1 454 SENTHAMARAI 67 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
2 186 JOTHI 49 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
3 455 NARAYANAN 70 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
4 194 JAYALAKSHMI 50 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
5 198 NAGAMAL 58 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
6 475 BOOPTHAY 60 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
7 482 ABDUL JHADER 52 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
8 207 SAGUNTHALA 46 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
9 481 CHINNAKANNU 51 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
10 223 PADMAVATHI 65 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
11 498 GANESAN 56 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
12 507 SELVAM 40 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
13 509 BALU 51 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
14 510 KARUPPAN 55 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
15 515 PERUMAL 50 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
16 241 CHANDARA 55 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
17 246 LALITHA BAI 65 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
18 530 BASAVARAJAN 70 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
19 251 MAYAVADHI 50 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
20 257 YAMUNA BAI 53 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
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S.NO OPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
21 S510 K.SANTHANAM 63 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
22 S1205 MUTHULAKSHMI 53 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
23 S2585 LOGANATHAN 60 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
24 S2861 RAJAKUMARI 43 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
25 S2973 SAKUM\NTHALA 57 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
26 M9760 SEENU 55 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
27 S6119 SANTHYA 44 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
28 S7163 RAMILA 42 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
29 S9410 SANMUGAVALLI 58 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
30 S9944 RAJU 65 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
31 S9802s UNAMALAI 47 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
32 T270 DHAKSHANAMURTHY 61 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
33 T1935 RAJENDERAN 52 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
34 T2034 TULASI 65  Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
35 T2529 JANABAI 50 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
36 T3015 PONNAMMAL 50 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
37 T4330 VIJAYLAKSHMI 52 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
38 T4521 KAUSHALYA 55 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
39 T5524 RAJAMANI 59 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
40 T5766 ARUMUGAM 46 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
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S.NO OPNO NAME AGE SEX 
1ST DAY 24TH DAY 48TH DAY 
OV
A 
CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
OVA CYST OCCULT 
BLOOD 
PUS 
CELLS 
41 T6419 RAJI 50 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
42 T7414 MARIAMMAL 63 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
43 T8561 RAJ KUMAR 48 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
44 T8605 MOHANRAJ 59 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
45 T8665 PUSHPA RANI 56 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
46 T8904 ETHIRAJULU 78 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
47 T9225 MANIKAM 65 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
48 T9020 VALLI 47 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
49 U1095 CHANDRAPILLAI 59 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
50 U1136 KANNIA 50 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
51 U1494 THIRUNAUKARASU 69 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
52 S7163 KANNATAHL 55 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
53 U6091 KANCHANA 52 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
54 U6499 DAHANALAKSHMI 62  Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
55 U7214 DHARMARAJAN 62 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
56 U7552 KASTURI 55 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
57 U8708 ALAMELU 50 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
58 U8566 ALLAPICHAI 60 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
59 T7348 SARASWATHI 55 F Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
60  FATHIMA 45 M Nil Nil Negative Nil Nil Nil Negative Nil Nil Nil Negative Nil 
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AND POOCHU ENNAI) FOR AZALKEELVAYU (OSTEOARTHRITIS) 
CONSENT FORM 
Certificate by Investigator 
 I certify that I have disclosed all details about the study in the terms readily understood 
by the Patient. 
 
Date :__________________     Signature ____________ 
 
        Name _________________ 
Consent by Patient 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow – up including the laboratory 
investigations to be performed to monitor and safeguard my body functions.  
 
 I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 
 I, exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of “Mirutharsingi Chunnam and Poochu Ennai”  for the management 
Azalkeelvayu (OsteoArthritis)  
 
Date:      Signature 
 
      Name: 
 
      Signature of Witness 
 
      Name: 
 
      Relationship: 
                                                    
 
 
 
 
   DIET RESTRICTIONS 
 
I. PULSE VARIETIES: 
 
1. Bengal gram  
2. Green gram 
3. Garden pea  
4. Dolichos 
5. Cow pea 
6. Black gram 
7. Horse gram 
 
 
II.GETABLES: 
                     
1. Tender bean  
2. Plantain 
3. Bottle gourd 
4. Ash gourd 
5. Pumpkin 
6. Snake gourd 
7. Sponge gourd 
8. Bitter gourd 
9. Cucumber 
10. Mango 
                                                                                                                             
III.TUBERS: 
 
1. Potato 
2. Cassara plant tuber 
IV.FLESH:      Chicken 
 
V. MEAT:        
1. Pork 
2. Beef 
3. Sambar meat 
 
VI. OTHERS: 
1. Salty foods 
2. Sour foods 
3. Spicy foods  
4. Fatty foods 
5. Flours         
6. Cool drinks 
7.mustard seed 
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AN OPEN TRIAL OF SIDDHA TREATMENT (MIRUDHARSINGI CHUNNAM 
AND POOCHU ENNAI) FOR AZALKEELVAYU (OSTEOARTHRITIS) 
 FORM – II ASSESSMENT PROFORMA 
1. IP / OP No.:   2. Bed No.:   3. S.No.: 
4.  Name:________________________________________________ 
5. Date of Admission to the trial :   
6. Date of Assessment: 
7.  Day of Assessment: 
   CLINICAL ASSESSMENT 
 Right Left 
Rel.(1)   Dim.(2)  Per.(3) Agg. (4) NA. (5) Rel.  (1) Dim. (2) Per. (3) Agg. (4) NA. (5) 
          8. Pain:           
          9.  Sweeling:           
        10. Warmth:           
        11. Tenderness:           
            1. Joint Line           
          2.  Medial side           
          3. Lateral Side           
4. Supra patellar             
       12. Morning  
                     Stiffness: 
         13. Crepitations: 
          
          
       14. Pertart.Mus. 
                     Atrophy: 
          
        15. Instability:           
        16.  Deformity:              
        17. Restricted  
                Movements: 
          
        
       18.  Circumference of the joint (cm) :           Right    Left  
 19  Naadi:   1.Vatham          2.Pitham         3.Kabam         4. Vatha Pitham          5. Vatha Kabam  
6.Pitha Kabam    7. Pitha Vatham     8. Kaba Vatham      9.Kaba Pitham 
            
            Rel. (1) – Relived 
            Dim..(2) – Diminished 
            Per.   (3) – Persists 
            Agg. (4) – Aggravated 
            NA   (5) – Not Applicable 
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 20.  Neerkuri:   Normal (1) Affected (2) 
    1.  Niram   
    2.  Manam         
    3.  Edai        
    4.  Nurai   
    5.  Enjal      
21. Neikuri : 1. Vathaneer  2.Pithaneer    3. Kabaneer 
22. Blood Pressure (mmHg) 
23. Heart rate / min   
24. Pulse rate / min 
 
  
LAB INVESTIGATION (Only on days 24 and 48) 
 
BLOOD 
 
25. TC (Cells/Cumm): 
  
      DC (%):   26.N   27.L   28.M  
29.E        30.B  
  
31. ESR (mm) : ½ Hr:    32. ESR (mm) :1 Hr: 
33. Hb (gm%)  :       .      .        
   Blood Sugar (mg%):   34. Fasting                    35 . Post – prandial  
                                    36. Random              
37. Blood Urea  (mg%) :  
                                                    
38. Serum Cholesterol (mg%):  
                          
                 URINE 
                                                
39. Albumin   -  0. Nil            1. +             2. + +           3.  + + +          
          
40. Sugar        - 0. Nil            1. +             2. + +           3.  + + +                                                                 
41. Deposit : 1. Pus cells                    2. Epithelial cells                      3. Red blood cells 
                   4. Casts/Crystal    0. Nil             1. Present 
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 MOTION              Present (1)         Absent (2) 
42. Ova   - 
43. Cyst   - 
44. Occult blood - 
45 Pus cells  - 
RADIOLOGICAL INVESTIGATION (Only on day 48) 
         
46. X- Ray Findings: 1. Improved  2. No Change  3. Not done 
 
  FOR O.P. PATIENTS: 
47. Drugs returned 
  1. No. of Packets(65 mg) : 
  2. Volume of Thylum(ml) 
48.  Drugs Issued:  
   1.  No of Packets (65 mg): 
   2. Volume of Thylum (ml): 
49. RESULT: 
   1.Cured    2.Improved   3.No Change   
 
50.  Date:___________________   51. Signature of Doctor: ______________  
52.  Station: ___________________   53. Signature of H.O.D.: ______________ 
        
PROTOCOL 
 
NATIONAL INSTITUTE OF SIDDHA, CHENNAI - 47 
 
AN OPEN TRIAL OF SIDDHA TREATMENT (MIRUTHARSINGI CHUNNAM 
AND POOCHU ENNAI) FOR AZALKEELVAYU (OSTEOARTHRITIS) 
Dr. M. ANBUTHANGAM 
 
1. BACKGROUND  
 
Osteoarthritis is a non inflammatory disorder of movable joints characterized by detorioration of 
articular cartilage and formation of new bone at the joint surfaces and margins. This disorder is also known   as 
degenerative joint disease. Knee joints osteoarthritis is the leading cause of chronic disability in developed 
countries. The distribution of osteoarthritis in men & women is similar. Ages between 40-65Yrs commonly 
affected. In this age group, the prevalence is 68%. 
In our siddha system, the term osteoarthritis is compared to Azalkeelvayu   
According to siddha literature, Azalkeelvayu is one of the types of keelvayu diseases. Keelvayu Disease 
is one among the 80 Vathadiseases that is called Santhuvatham. It is also called as Mootuvali, Santhusoolai. 
About the disease 
 
 
 
 
 
 
In siddha text, “Korakkar Santhraregai” there is a preparation named “Mirutharsingi Chunnam” 
which is indicated for vatham 80. In Ugimunivaithyakaaviam text, there is an external application named 
“poochu ennai” which is indicated for muzhangalpiddipu. 
So, I would like to estimate their efficacy in a open trial in the  OPD & IPD  patients at the National 
Institute of Siddha, Chennai -47. 
2. AIMS 
(a) Primary aim  
To estimate the efficacy of “ Mirutharsingi Chunnan” and “Poochu ennai” in the treatment of 
Azalkeelvayu 
(b) Secondary aim 
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To find out the side effects or adverse reactions of the drugs, if any. 
 
 
 
 
3.  POPULATION & SAMPLE 
 
The population consists of all patients with Azalkeelvayu satisfying the inclusion and exclusion criteria 
mentioned below. The trial will be a single centric, open clinical trial. The sample consists of patients attending 
the IPD/OPD of the Ayothidoss pandithar Hospital of the National Institute of Siddha, Chennai – 47. 
 
4.  SAMPLE SIZE 
The trial size will be 50 patients  
 
5. INCLUSION CRITERIA 
1. Patients who are having classical symptoms of Azalkeelvayu 
2. Aged between 40 – 65yrs. 
3. Willing to give blood specimen & willing to take X-ray for the investigation when required. 
4. Willing to be in – patient for 49 days, or willing to attend OPD once in 8 days for 48 days 
6.  EXCLUSION CRITERIA 
Patients with hypertension,  stomach carcinoma, Peptic Ulcers, hypercholestremia,  and patients with 
any serious illnesses  
7. WITHDRAWAL CRITERIA 
1. Any drastic changes occurring in hematological parameters & in urine analysis. 
2. Development of any gastro-intestinal disturbances. 
3. Occurrence of any other serious illness.  
 
8. TRIAL DRUG & DURATION 
 Purgation: 
                Sithathi ennai  - 5ml with sombukudineer (at  early morning) – one day 
Internal drug: 
    Mirutharsingi chunnam –  65 mg with Ghee – twice a day after food 
External Application: 
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    Poochu ennai  - 30ml - External application 
Trial treatment period  - 48days. 
9. TESTS & ASSESSMENTS  
(a) Clinical assessment 
 Pain, swelling, warm, redness, tenderness, morning stiffness,   crepitations, peri articular muscle 
atrophy, Movements of the joints, measurements of the joints in both knee joints. 
(b) Investigations 
1. Blood test: TC, DC, ESR, HB, Blood Urea, Serum Cholesterol, Blood Sugar. 
2. X-ray findings. 
 
10. CONDUCT 
Azalkeelvayu patients satisfying inclusion & exclusion criteria will be admitted to the trial. 
Informed consent will be obtained from the patients. 
A day before starting trial treatment, neutralizing of Mukkutras by purgation will be carried out. 
X-ray will be taken before treatment and at the end of the treatment  
Lab investigations will be carried out before treatment on 24th day and at the end of the treatment  
For IP patients, the trial drug   will be administered by the doctor. For op patients, the trial drugs will be 
issued for 8 days.  They will be asked to come to op with unconsumed medicines and return them. On the 8th 
day, the trial drug will be given to the patient for another 8 days. At each clinic visit, clinical assessment will be 
taken. On 24th and 48th day, lab investigations will be carried out. 
 
11. FORMS 
 
Form I - Selection proforma - Used before admission of the patients to the trial. 
Form II - Assessment form -Used once in 8 days during treatment. 
 
12. ANALYSIS 
 
Changes in the proportion of patients before and after treatment for signs and symptoms will be analysed 
using paired X2 - test. 
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FORM I – SELECTION PROFORMA 
 
 
1.  OP / IP NO:                              2.BED NO:  3. S.NO : 
 
4.  NAME    :     5. AGE :  6. GENDER: M          F 
 
7.  MARITAL STATUS:        1. SINGLE                         2.  MARRIED    
 
                                                 3. WIDOW          4. SEPERATED  
 
8. DATE OF ADMISSION TO THE TRIAL:  
 
9. OCCUPATION:  
 
10. POSTAL ADDRESS: 
    
 
 
 
11.  COMPLAINTS & DURATION: 
 
 
 
 
 
 
 
 
 
 
12. HISTORY OF PRESENT ILLNESS: 
 
 
 
 
 
 
 
 
 
 
13.  PAST HISTORY: 
   Injury   Fractures  Not Applicable 
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14.  FAMILY HISTORY:    1. NO            2. YES              
 
15.  MENOPAUSE:  1. ATTAINED   2. NOT ATTAINED        3. NOT APPLICABLE  
 
16. SOCIAL STATUS:  1. LOW         2. MIDDLE    3. HIGH  
 
HABITS 
               Yes (1)            No (2) 
17. SMOKER 
18. ALCOHOLIC 
19. BETALNUT & TOBACCO CHEWER 
20. NON – VEGETARIAN 
GENERAL EXAMINATION 
21. BODY WEIGHT (Kg) 
 
22. BODY TEMPERATURE (°F)         .      
 
23. BLOOD PRESSURE (mmHg)    
 
24. HEART RATE / min   
 
25. RESPIRATORY RATE / min 
 
26. PULSE RATE / min 
Yes (1)  No (2) 
 
27. PALLOR 
 
28. JAUNDICE 
 
29. CLUBBING 
 
30. CYANOSIS 
 
31. PEDAL OEDEMA 
 
32. LYMPHADENOPATHY 
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CLINICAL EXAMINATION OF KNEE JOINTS: 
 
   Right    Left  Both 
 
33.  PAIN             Right            Left 
                      
            Aggravated by   Yes (1)     No (2)         Yes (1) No (2) 
   
1. Walking  
2. Climbing Upstairs  
3. Squatting  
4. Standing up  
5. Sitting Cross legged  
6. Reduces With Rest        
 
34. SWELLING:         
1. Present              1. Present 
       2. Absent              2. Absent   
35. WARMTH:        
1. Present              1. Present 
       2. Absent              2. Absent 
36. TENDERNESS:  
Yes(1)       No (2)        Yes (1)  No (2) 
1. Joint line  
2. Medial Side  
3. Lateral Side  
4. Supra Patellar         
37. MORNING STIFFNESS: 
     1.  Mild     1. Mild 
     2.  Moderate    2. Moderate 
     3.  Severe     3. Severe 
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38. CREPITATIONS :           Right              Left 
1. Present              1. Present 
       2. Absent              2. Absent 
39. PERIARTICULAR MUSCLE ATROPHY: 
1. Present              1. Present 
       2. Absent              2. Absent 
40. INSTABILITY: 
       0. Nil     0. Nil  
    1. Anteroposterior                         1. Anteroposterior 
     2. Mediolateral                         2. Mediolateral 
41. DEFORMITY:       Yes (1)    No (2)              Yes (1)    No (2) 
    1. Varus      
    2. Valgus        
    3. Flexion       
42. RESTRICTED MOVEMENTS OF THE JOINTS AT FLEXION: 
1. Present              1. Present 
      2. Absent              2. Absent 
43. GIRTH OF THE THIGH MUSCLE (in cm): 
            1.Right    2. Left  
 
44. CIRCUMFRENCE OF JOINTS (cm): 1. Right   2. Left 
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EXAMINATIONS OF VITAL ORGANS 
                                                           Normal (1)            Abnormal (2) 
 
45. CVS                _____________________ 
 
46. R.S        _____________________ 
 
47. ABDOMEN       _____________________ 
 
 
SIDDHA ASPECTS 
48. NILAM 
        1.   Kurinji             2.  Mullai           3.  Marutham          4 .Neithal 5.Palai 
49. KALA IYALBU 
        1.   Kaarkaalam         2.  Koothirkallam           3.   Munpanikaalam      
          4 . Pinpanikaalam  5. Ilavenirkaalam         6.Muduvenirkaalam 
50. UDAL IYALBU 
 1.Vatham  2.Pitham  3.Kabam  4. Vatha Pitham 5. Vatha Kabam  
6.Pitha Kabam    7. Pitha Vatham     8. Kaba Vatham      9.Kaba Pitham 
51. GUNAM 
 1.Sathuvam  2.Rasatham  3.Thamasam 
   AYMPORIGAL 
      Normal (1)    Affected (2)   
52. Mei  
53. Vaai   
54. Kan  
55. Mookku   
56. Sevi  
  
KANMENDHIRIUM / KANMAVIDAYAM 
   Normal (1)    Affected (2)    
57. Kai        
58. Kaal 
59. Vaai  
60. Eruvaai  
61. Karuvaai  
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UYIR THATHUKKAL 
   VATHAM 
             Normal (1)    Affected (2) 
62. Pranan     
63. Abanan    
64. Viyanan            
65. Uthanan      
66. Samanan                              
67. Nagan    
68. Koorman   
69. Kirukaran         
70. Devathathan     
71. Dhananjeyan   
PITTHAM 
                       Normal (1)    Affected  (2) 
72. Anar pittham         
73. Ranjagam   
74. Sathagam        
75. Alosagam                
76. Prasagam 
KABAM 
                  Normal (1)    Affected  (2) 
 77. Avalambagam 
78. Kiletham     
79. Pothagam          
80. Tharpagam       
81. Santhigam 
   UDAL THATHUKKAL 
                           Normal (1)   Affected (2) 
 82. Saaram            
83. Senneer               
84. Oon            
85. Kozhuppu            
86. Enbu             
87. Moolai           
88. Sukkilam / 
     Suronitham 
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ENVAGAI THERVUGAL 
                 Normal (1)    Affected (2) 
89. Naa                    
90. Niram          
91. Mozhi        
92. Vizhi               
93. Sparisam 
94. Naadi   
    1.Vatham     2.Pitham      3.Kabam      4. Vatha Pitham       5. Vatha Kabam  
    6.Pitha Kabam    7. Pitha Vatham     8. Kaba Vatham      9.Kaba Pitham 
Malam 
                Normal (1)    Affected (2) 
       95.  Niram:     
 96.  Nurai:       
 97.  Kirumi:   
 98.  Kalappu: 
 99. Thanmai:          Erugal         /   Elagal 
MOOTHIRAM 
Neerkuri  
          Normal (1)     Affected (2) 
100.  Niram   
101.  Manam         
102.  Edai        
103.  Nurai   
104.  Enjal      
 
Neikuri 1.Vatha Neer  2.Pitha Neer  3. Kaba Neer 
 
 
LAB INVESTIGATIONS 
BLOOD 
105. TC (Cells/Cumm): 
  
        DC (%):   106.N   107.L   108.M  
     109.E     110.B  
  
111. ESR (mm) : ½ Hr:    112. ESR (mm) :1 Hr: 
113. Hb (gm%)  :     .   
Blood Sugar (mg%):114. Fasting                        .     115 . Post – prandial                         . 
                                116. Random                       .  
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117. Blood Urea  (mg%) :  
                                                    
118. Serum Cholesterol (mg%):  
                          
  
URINE 
                                                
119. Albumin   -  0. Nil            1. +             2. + +           3.  + + +          
          
120. Sugar        - 0. Nil            1. +             2. + +           3.  + + +                                                                
121. Deposit : 1. Pus cells                 2. Epithelial cells            
                    3. Red blood cells   4. Casts/Crystal  0. Nil             1. Present 
 
 MOTION     Present (1)         Absent (2) 
122. Ova   - 
123. Cyst  - 
124. Occult blood - 
125. Pus cells  - 
RADIOLOGICAL INVESTIGATION 
       AP  
126. X- RAY:  KNEE JOINTS   View - Standing 
       Lat  
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
______________________________________________________________________________ 
 
127 .Admitted to trial:  1.Yes  2. No    
128. If Yes, S.No.:   129.  IP (1)           OP (2) 
130. Date of purgation: 
Drugs issued for O.P. patients.  
131.  No. of Packets    (65 mg):      
132.  Volume of Thylum (ml):      
 
133. Date : _______________    135.  Signature of Doctor: ____________  
134. Station:_______________    136.  Signature of H.O,D: ____________ 
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Form – II Assessment Form 
1. IP / OP NO:   2. BED NO:   3. S.NO: 
4.  NAME:________________________________________________ 
5. DATE OF ADMISSION:   
6. DATE OF ASSESSMENT: 
7.  DAY OF ASSESSMENT: 
CLINICAL ASSESSMENT 
 1. Relieved 2. Diminished 3. Persistent 4. Aggravated 5. No 
Rt.Jt Lt.Jt Rt.Jt Lt.Jt Rt.Jt Lt.Jt Rt.Jt Lt.Jt Rt.Jt Lt.Jt 
 8. PAIN:           
 9.  SWEELING:           
10. WARM:           
11. REDNESS:           
12. TENDERNESS:           
13.  MORNING 
       STIFFNESS: 
          
14. CREPITATIONS:           
15. RESTRICTED 
      MOVEMENT: 
          
 
16. MEASUREMENTS:     Right (cm)   Left (cm) 
17.  Naadi: ____________________________________________ 
18  Neerkuri: __________________________________________ 
19. Neikuri : __________________________________________ 
 LAB INVESTIGATIONS 
BLOOD 
20. TC (Cells/Cumm): 
  
      DC (%):   21.N   22.L   23.M  
24.E        25.B  
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26. SR (mm) : ½ Hr:    27. ESR (mm) :1 Hr: 
28. Hb (gm%)  :       .            . 
 
 Blood Sugar (mg%):   29. Fasting                     30 . Post – prandial  
                                 31. Random              
32. Blood Urea  (mg%) :  
                                                    
33. Serum Cholesterol (mg%):  
                          
 URINE 
                                                
34. Albumin   -  0. Nil            1. +             2. + +           3.  + + +          
          
35. Sugar        - 0. Nil            1. +             2. + +           3.  + + +                                                                 
36. Deposit : 1. Pus cells          2. Epithelial cells           3. Red blood cells 
                   4. Casts/Crystal 
MOTION              Present (1)         Absent (2) 
37. Ova   - 
38. Cyst  - 
39. Occult blood - 
40. Pus cells  - 
RADIOLOGICAL INVESTIGATION: 
         
41. X- Ray Findings: 1. Improved  2. No Change  3. Not Applicable  
 
FOR O.P. PATIENTS: 
42. Drugs returned 
  1. No.of Packets(mg) : 
  2. Volume of Thylum(ml) 
43.  Drugs Issued:  
   1.  No of Packets (mg): 
   2. Volume of Thylum (ml): 
44. RESULT: 
   1.CURED   2.IMPROVED   3.NOCHANGE   
 
45.  Date:___________________       
 11
46.  Station: ___________________   47. Signature of 
Doctor______________ 
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CONSENT FORM 
Certificate by Investigator 
 I Certify that I have disclosed all details about the study in the terms 
readily understood by the Patient. 
 
Date :__________________    Signature ____________ 
 
        Name _________________ 
Consent by Patient 
 I have been informed to my satisfaction, by the attending physician, the 
purpose of the clinical trial, and the nature of drug treatment and follow – up 
including the laboratory investigations to be performed to monitor and 
safeguard my body functions.  
 I am aware of my right to opt out of the trial at any time during the 
course of the trial without having to give the reasons for doing so. 
 I, exercising my free power of choice, hereby give my consent to be 
included as a subject in the clinical trial of “Mirudharsingi Chunnam and 
Poochu Ennai”  for the management Azalkeelvayu (OsteoArthritis)  
 
Date:      Signature 
 
      Name: 
 
      Signature of Witness 
 
      Name: 
 
      Relationship: 
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   DIET RESTRICTIONS 
 
I. PULSE VARIETIES: 
 
1. Bengal gram  
2. Green gram 
3. Garden pea  
4. Dolichos 
5. Cow pea 
6. Black gram 
7. Horse gram 
 
 
II.GETABLES: 
                     
1. Tender bean  
2. Plantain 
3. Bottle gourd 
4. Ash gourd 
5. Pumpkin 
6. Snake gourd 
7. Sponge gourd 
8. Bitter gourd 
9. Cucumber 
10. Mango 
                                                                                                                             
III.TUBERS: 
 
1. Potato 
2. Cassara plant tuber 
IV.FLESH:      Chicken 
 
V. MEAT:        
1. Pork 
2. Beef 
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3. Sambar meat 
 
VI. OTHERS: 
1. Salty foods 
2. Sour foods 
3. Spicy foods  
4. Fatty foods 
5. Flours         
6. Cool drinks 
7.mustard seed 
 
        
